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ABSTRACT 
Melissa A. Babilonia-Rosa: The Role of Lipase Maturation Factor 1 in the Maturation of 
Lipoprotein Lipase 
(Under the direction of Saskia Neher) 
 
Over a third of the US adult population has elevated blood triglyceride (TG) levels 
(hypertriglyceridemia), resulting in an increased risk of atherosclerosis, pancreatitis, and 
metabolic syndrome. Lipases are responsible for lipid uptake from dietary sources and 
for the distribution of fatty acids to different tissues. Lipoprotein lipase (LPL), a dimeric 
enzyme, is the main lipase responsible for TG clearance from the blood after food 
intake. In difference of monomeric lipases, dimeric lipases require lipase maturation 
factor 1 (LMF1) for proper folding, activity, and secretion. LMF1 is a transmembrane 
protein located in the endoplasmic reticulum (ER). Although LMF1 is crucial for ER exit 
of dimeric lipases, the mechanism by which LMF1 promotes lipase maturation is not 
known. My thesis work aims to understand LMF1's role in LPL maturation using cell 
biology and biochemical methods. I have developed N-terminal truncation mutants of 
LMF1, which revealed that full length LMF1 is required for the maturation of LPL. We 
employed LMF1-crosslinking/mass spectrometry studies to identify proteins with a role 
in LPL maturation. Our novel interacting partners of LMF1 and LPL were validated by 
pull down assays and by protein knockdowns to assess effects on LPL maturation.  
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We found five novel, ER-resident binding partners of LMF1. Three of these 
proteins are involved in formation and isomerization of disulfide bonds. Given the role in 
oxidative folding of most of the new partners we propose that LMF1 promotes LPL 
folding by promoting redox homeostasis in the ER. 
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 INTRODUCTION CHAPTER 1:
The lipase gene family 
Lipases are hydrolases present in organisms ranging from prokaryotes to 
humans that mediate the absorption, transport, storage, and mobilization of lipids. Here, 
we focus on the dimeric lipases lipoprotein lipase (LPL), hepatic lipase (HL), and 
endothelial lipase (EL). These three lipases belong to the same gene family1,2. They 
reside in the capillary lumen, anchored to the endothelial lining where they hydrolyze 
lipids from lipoproteins, releasing fatty acids that can be absorbed by neighboring tissue 
for triglyceride (TG) and phospholipid clearance from the plasma. The three lipases 
differ in the tissues in which they are expressed and in their substrate specificity. LPL is 
mainly expressed in the heart, adipose tissue, and skeletal muscle but mRNA 
expression has been reported in the brain, lung, adrenal gland, and placenta3-5. LPL 
activity has been detected in heart, adipocytes, muscle, lungs, kidney and brain6. HL is 
synthetized mainly in the liver but its also expressed in macrophages7. In contrast to 
LPL and HL which are expressed in different cell types but active at the endothelial 
lining of the capillary lumen, EL is synthetized by endothelial cells and northern-blot 
analysis across different human tissues show mRNA expression in the lungs, liver, 
placenta, and kidneys4. In terms of substrate specificity, LPL primarily hydrolyzes TG, 
EL is primarily a phospholipase, and HL can hydrolyze both substrates8. 
Pancreatic lipase (PL) is another member of the lipase gene family and it resides 
in the intestines where it hydrolyzes TG from dietary fats. Phylogenic analysis of the 
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lipase gene family suggests that PL diverged from an ancestral lipase previous to the 
dimeric lipases1,9. EL was the last lipase member to be identified; its primary sequence 
is 45% homologous to LPL, 40% homologous to HL, and 27% homologous to PL4. A 
combination of site directed mutagenesis and computational studies have revealed 
these lipases share an active serine site within a characteristic pentapeptide sequence 
GXSXG10-13. In addition to sequence similarity, these four lipases share structural 
features. PL is the only one of these lipases with a known structure14. Computational 
modeling studies based on crystal structures of PL from horse, porcine, and human14-17 
suggest that EL, LPL, and HL contain an N-terminal domain that is responsible for their 
catalytic activity. The N-terminal domain harbors a (Ser-Asp-His) catalytic triad with a 
α/β hydrolase fold13,18 (Fig. 1.1). The N-terminus also harbors the lid, which confers 
substrate specificity and covers the catalytic site in the closed conformation preventing 
substrate hydrolysis. Activity studies performed with chimeras comprised of LPL’s body 
and HL’s lid, or HL’s body and LPL’s lid, reveal that lid exchange is sufficient to change 
the substrate specificity of the LPL chimera from TG to phospholipids whereas the HL 
chimera gains specificity towards phospholipids19. The lid contains an amphipathic 
helix-turn-helix motif that is important for the physiological function of LPL and HL as 
revealed by site-directed mutagenesis studies20. This study also revealed that replacing 
the 22 amino acid lid of LPL with a shorter lid of 4 amino acids enhances hydrolysis of a 
short chain TG substrate such as tributyrin but abolishes hydrolysis of a long chain TG 
substrate like triolein. The C-terminal domain has a β-sandwich fold which contains a 
heparin binding site for LPL and HL. Additionally, a tryptophan cluster in the C-terminus 
of LPL is important for substrate recognition18,21.  
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Figure 1.1 Model of an LPL monomer. 
I-TASSER22 was used to obtain a predicted 3D structure of human LPL. The catalytic 
triad (Ser132 - Asp156 - His241) is shown in yellow. The lid covering the catalytic triad is 
shown in magenta with the stick representation of disulfide bond at the end of the lid. 
Michael Lafferty generated this model based on sequence similarity to pancreatic lipase. 
 
 
C-terminal N-terminal 
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Lipoproteins are important for the transport of TGs within the capillary lumen. 
They consist of a hydrophobic core of TGs and cholesteryl esters, and a hydrophilic 
surface that consists of phospholipids, cholesterol, and proteins known as 
apolipoproteins23,24. There are five types of lipoproteins synthetized in different tissues 
and categorized according to particle density; a property that changes with lipid and 
protein composition (Fig. 1.2A). Chylomicrons (CM) are the most buoyant lipoproteins 
as they have the most TGs in their core. They are synthesized in the small intestines by 
enterocytes from re-esterified fatty acids generated from the hydrolysis of dietary TGs 
by PL. Newly synthesized CMs enter the capillary lumen through the lymphatic system 
to deliver TG to peripheral tissues (Fig. 1.2B). Very-low density lipoprotein (VLDL) is the 
lipoprotein with the second highest TG content. The liver secretes VLDL to redistribute 
TG to adipose, heart, and muscle tissue. Upon TG hydrolysis by LPL in the capillary 
lumen, the TG content of CM and VLDL decreases by ~90% generating lipoproteins25 of 
higher density. Chylomicrons are released to the capillary lumen in the fed state 
whereas VLDL is secreted upon fasting. CM are transformed into CM remnants and 
VLDL is transformed to intermediate-density lipoprotein (IDL) and subsequently to low-
density lipoprotein (LDL). High-density lipoprotein (HDL) is critical for reverse 
cholesterol transport as it moves cholesterol from peripheral tissues to the liver. 
Substrate specificity of the lipases expressed at the capillary lumen allows for 
different lipoprotein preference and in consequence, the role of these lipases in 
lipoprotein metabolism varies. LPL hydrolyzes CM and VLDL (Fig. 1.2B), thus there is 
an accumulation of these lipoproteins in humans with LPL deficiency26,27. Conversely, 
LPL overexpression in mice results in decreased levels of plasma TG28. HL converts 
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IDL to LDL and post-prandial TG-rich HDL into TG-poor HDL29. Thus HL knockout mice 
have elevated total cholesterol and HDL cholesterol while TG levels remain comparable 
to WT mice (mice display only mild dyslipidemia following targeted inactivation of the 
hepatic lipase gene). Lastly, EL is primarily a phospholipase; hence it hydrolyzes 
phospholipids in HDL. As a result, EL overexpression in mice lowers HDL levels and 
mice knockouts have higher HDL levels when compared to control mice30. 
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A. 
Figure 1.2 Role of lipoproteins and LPL in TG transport in the capillary lumen. 
A) Characteristics of lipoproteins as modified from Biggerstaff et. al. 2004. The orange 
cartoons are a visual representation of the particle size. B) CM and VLDL are TG dense 
lipoproteins synthetized in the small intestines and liver, respectively. Both of these 
lipoproteins are secreted into the capillary lumen where they interact with LPL for TG 
hydrolysis. The fatty acids released are used for energy production or storage in 
adipocytes, heart, and muscle. 
B. 
Intestines Liver 
7 
Regulation of LPL activity by interacting proteins 
LPL is the rate-limiting enzyme for the hydrolysis of TG within the capillary 
lumen. LPL activity rises in white adipose tissue (WAT) after feeding while it declines in 
the heart and muscle; this leads to TG storage in adipocytes. The opposite effect is 
seen during fasting, LPL activity in the muscle and heart increases where the released 
fatty acids are used for storage or oxidized to generate energy. LPL within the capillary 
lumen is regulated by interacting partners such as apolipoproteins, angiopoietin-like 
proteins, and glycosylphosphatidylinositol-anchored high-density lipoprotein binding 
protein 1 (GPIHBP1).  
Plasma lipoproteins contain apolipoproteins that interact with LPL and modulate 
its activity. Apolipoprotein C-II (ApoCII) and AV (ApoAV) are known to promote LPL 
activity whereas ApoCI and CIII inhibit LPL31. ApoCII is mainly synthesized in the liver 
and it is a 79 amino acid peptide constituent of CM, VLDL, LPL and HDL32. In vitro 
activity assays with LPL purified from rat and ApoCII purified from VLDL or HDL 
revealed that ApoCII is a cofactor for LPL33. Furthermore, individuals with mutations in 
ApoCII accumulate TGs in the plasma because LPL needs ApoCII for efficient CM and 
VLDL hydrolysis34,35. The N-terminal domain of ApoCII contains the lipid-binding domain 
and the C-terminal domain interacts with LPL35. Crosslinking experiments of ApoCII with 
bovine LPL revealed a region of 11 amino acids in the N-terminus of ApoCII that bind to 
LPL36.  
ApoCI and CIII are mainly synthesized in the liver and they associate with CM, 
VLDL, and HDL37. Overexpression of either ApoCI or CIII in mice promotes an increase 
in TG levels38,39. Similarly, mice knockouts CIII have reduced plasma TG levels and 
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APOCIII loss of function mutations in humans are associated with reduced TG levels 
and reduced risk for coronary heart disease40-42. However, ApoCI knockout mice only 
show a trend towards lower TG levels and it seems that ApoCI impairs the binding of 
VLDL to the VLDL receptor thus resulting in VLDL accumulation in mice overexpressing 
ApoCI43. Another possible explanation for the inhibition of LPL activity by this 
apolipoproteins is LPL displacement from the lipoproteins44. Due to the discrepancy 
between in vitro and in vivo studies, further studies are needed to clarify the roles of 
ApoC1 and CIII in TG metabolism. 
ApoAV is also predominantly expressed in the liver and it associates with VLDL 
and HDL45. Transgenic mice overexpressing ApoAV have a 66% reduction in TG levels 
while mice knockouts display a 4-fold increase in TG levels when compared to 
controls46. Supporting the involvement of ApoAV in TG metabolism, loss of function 
mutations in humans lead to severe hypertriglyceridemia47,48. Two in vitro studies 
support the hypothesis that ApoA5 increases LPL activity45. Recombinant ApoAV 
stimulates LPL activity: 1) with addition of ApoCII and 2) with addition of VLDL isolated 
from mouse plasma. However, other in vitro studies do not support the hypothesis of 
ApoAV as an LPL activator. The conflicting data might result from utilization of different 
substrates. Other modes of action proposed for ApoAV have been intracellular 
repression of VLDL synthesis or activation of receptor mediated lipoprotein endocytosis 
in the liver31. Further studies are necessary to further understand the role of ApoAV in 
TG metabolism. 
The angiopoietin-like protein (ANGPTL) family is comprised of eight secreted 
proteins49. With the exception of ANGPTL8, family members have an N-terminal coiled-
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coil domain and a C-terminal fibrinogen like domain. Three family members, ANGPTL3, 
4 and 8, are known to alter TG metabolism by inhibition of LPL’s activity. ANGPTL3 and 
4 are cleaved by protein convertases like FURIN releasing the N-terminal domain, 
which inhibits LPL. This cleavage is crucial for LPL inhibition. ANGPTL4 functions as a 
homo-oligomer and studies from our lab have revealed that ANGPTL4 is a reversible 
inhibitor of LPL50. ANGPTL8 lacks the C-terminal domain characteristic of the family but 
the N-terminal domain still shares 20% sequence identity with ANGPTL3 and 4, 
suggesting similar functions51. This region includes the ~25 residues of ANGPTL3 and 4 
known to bind LPL52. Adenoviral expression of ANGPTL8 in mice liver results in 
increased plasma TG levels whereas co-expression of ANGPTL8 and 3 further 
exacerbate TG accumulation; expression of ANGPTL3 alone does not alter TG levels53. 
Additionally, co-immunoprecipitation studies from plasma of these mice show that 
ANGPTL8 interacts with the N-terminal domain of ANGPTL3. Lastly, the N-terminal 
domain of ANGPTL3 is released into the media of hepatocytes co-expressing 
ANGPTL8 and 3 whereas cells expressing only ANGPTL3 release full-length protein. 
Taken together, these findings suggest that ANGPTL8 inhibits LPL in an ANGPTL3-
dependent manner.   
ANGPTL3, 4, and 8 mediate LPL inhibition but they do so in different tissues and 
at different times in the fed-fasting cycle54. ANGPTL4 inhibits LPL in WAT while 
ANGPTL4 and 8 work in the heart and skeletal muscle. Fasting upregulates ANGPTL4, 
which downregulates LPL’s activity in adipose tissue. Conversely, fasting 
downregulates ANGPTL8 so LPL remains active in the heart and muscle. As a result, 
during fasting, LPL in the heart and muscle hydrolyzes TG from chylomicrons and VLDL 
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providing fatty acids to be oxidized for energy. After a meal, ANGPTL4 is downregulated 
while ANGPTL8 is upregulated. In consequence, LPL remains active in WAT and 
inactive in the heart/muscle. 
The mechanism by which LPL reaches the capillary lumen remained a mystery 
until GPIHBP1 was discovered in 201055. Immunohistochemical studies with a 
fluorescently labeled antibody against GPIHBP1 revealed that GPIHBP1 is expressed in 
the capillary lumen in tissues from WT mice. In WT mice, LPL co-localizes with the 
GPIHBP1 and can travel to its site of action in the capillary lumen of these tissues. In 
mice lacking GPIHBP1, LPL becomes stuck in the interstitial spaces surrounding 
myocytes and adipocytes. This finding explains why GPIHBP1 deficient mice have 
severe hypertriglyceridemia56; LPL is not transported to the capillary lumen for 
hydrolysis of chylomicrons and VLDL. Confirmation of the role of GPIHBP1 in transport 
came from transwell assays using rat heart microvessel endothelial cells expressing 
GPIHBP157. When LPL is added to the basolateral chamber of the transwells, it is 
translocated to the apical chamber only in the presence of GPIHBP1. The acidic domain 
of GPIHBP1 is known to bind LPL58. A final transwell experiment confirmed that 
GPIHPB1 with a mutation in the acidic domain is not capable of translocating LPL to the 
apical surface of endothelial cells. Lastly, the fact that GPIHBP1 does not bind HL, EL 
or PL was demonstrated by expression of GPIHBP1 followed by addition of conditioned 
media containing each of the lipases separately59. Immunofluorescence experiments 
confirmed that only LPL binds to cells expressing GPIHBP1. 
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Post-translational modifications of LPL 
In order for LPL to be secreted in its active dimeric form, necessary post-
translational modifications include subunit assembly, glycosylation, and disulfide bond 
formation60. LPL is active as a noncovalent homodimer in a head to tail subunit 
arrangement61,62. Similarly, HL and EL are also homodimers with a head to tail 
orientation63,64 while PL is active as a monomer65. Dimerization of LPL, HL, and EL 
occurs in the ER where two populations of lipases can be found: 1) aggregated 
monomers that are inactive and eventually degraded and 2) active dimers that can exit 
the ER66,67.    
Like other glycosylated proteins68, members of the lipase gene family contain a 
glycan chain covalently attached to the consensus sequence Asn-X-Ser/Thr. 
Asparagine mutations at positions 43, 56, and 62 of LPL, HL, and EL respectively, result 
in missfolding defects leading to ER retention and abolishment of lipase activity69-71.  
Sequence alignment of PL, LPL, HL, and EL shows these lipases share ten 
cysteines that are conserved across species1,4 suggesting these residues have a role in 
the structure and function of these lipases. Disulfide bond pairing was determined 
sequencing disulfide linked tryptic peptides confirming the formation of 5 disulfide 
bonds72. Site directed mutagenesis of eight conserved cysteines demonstrates that six 
of the cysteines are critical for LPL activity73. The first conserved cysteine pair, 
C216/C239 for LPL, forms a disulfide bond in the lid of PL62,74 where it is important for 
the opening and closing movement of the lid thus is important for substrate hydrolysis. 
The other two other disulfide pairs important for LPL activity are C264/C275 and 
C278/C283. The disulfide bond in the C-terminus of LPL, C418/C438, retains 85% of 
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activity when compared to WT. However, C418 is important for interaction with 
GPIHBP1 although disulfide bond formation is not required for the interaction75. In 
agreement with these findings, individuals with the C418Y LPL mutant have severe 
hypertriglyceridemia76.  
LMF1 is necessary for secretion of dimeric lipases 
The relationship between dimeric lipases and lipase maturation factor 1 (LMF1) 
was discovered in 1983 in mice with an autosomal recessive mutation named combined 
lipase deficiency (cld)77. Mice homozygous for the cld mutation (cld/cld) appear normal 
at birth but they die within 48 hrs postpartum due to progressive triglyceride 
accumulation. However, heterozygous littermates (cld/wt) do not share this phenotype. 
Activity measurements of LPL and HL from heterozygous vs. homozygous cld mice 
revealed diminished lipase activity; subsequently impairment of EL activity was also 
demonstrated9. To understand why lipase activity levels are diminished in the plasma of 
cld/cld mice, mRNA levels of LPL and HL were measured from heart and liver and 
compared to heterozygous littermates78. Because mRNA levels are comparable for 
homozygous and heterozygous mice, the cld mutation was thought to affect protein 
synthesis or post-translational modifications. Pulse-chase experiments in heart and liver 
slices demonstrate that the rate of [35S] methionine incorporation was slightly slower 
when comparing homozygous and heterozygous mice. However, cld/cld mice also 
showed lower rates of overall protein synthesis as well which seemed to be a result of 
the inability of these mice to use dietary triglycerides78. The next step to determine if the 
cld mutation affected lipase processing was Endo H digestion. N-linked glycoproteins 
like LPL and HL are glycosylated by oligosaccharyltransferase, which transfers high 
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mannose oligosaccharides as proteins emerge from the translocon.  In the Golgi, high 
mannose units are removed and replaced by more complex sugars that are resistant to 
Endo H cleavage. As a result, Endo H treatment is used to probe accessibility of 
mannose units, which is correlated to the location of the glycosylated protein in the 
secretory pathway. Glycosylated proteins that have moved past the medial/trans-Golgi 
compartment are Endo H resistant whereas glycosylated proteins in the ER are Endo H 
sensitive79. Endo H treatment of liver immunoprecipitated LPL revealed that cld/cld mice 
only have LPL sensitive to Endo H. Thus LPL in these mice does not make it to the 
medial/trans-Golgi. However, LPL in the cld/+ mice is both Endo H sensitive and 
resistant, representing protein being processed in the ER (Endo H sensitive) and protein 
that has entered the secretory pathway (Endo H resistant). Similarly, HL 
immunoprecipitations from homozygous and heterozygous livers followed by Endo H 
treatment reveal that HL also has a secretion defect in cld/cld mice; all the HL is Endo H 
sensitive78. Thus mRNA and protein levels of LPL and HL in cld mice are not affected 
but newly synthetized protein is retained in the ER, preventing Golgi processing and 
lipase secretion. However, Endo H testing of a different glycoprotein demonstrated that 
the cld mutation does not affect all N-linked glycoproteins thus the cld mutation does not 
confer a global failure in the glycosylation pathway78. 
Even though the cld mutation was discovered in 1983, the characterization of the 
gene responsible for the cld mutation was delayed over two decades. The cld mutation 
mapped to t haplotypes in Chromosome 17; a chromosomal region that contains four 
blocks of inversions that were challenging to map because recombination suppression 
prevented classical mapping approaches77,80. Genetic crosses between complementing 
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t haplotypes were key to remove early acting lethal mutations and avoid recombination 
suppression. These studies revealed that the cld mutation localizes to the haplotype 
tw73, a region containing 149 genes. Genes to be tested were narrowed down by two 
methods. First, preference was given to genes involved protein folding or protein 
retention in the ER because it was known from the Endo H studies that LPL and HL in 
cld/cld mice does not move to the medial/trans-Golgi. Second, preference was given to 
genes demonstrating lower mRNA levels in homozygous vs. heterozygous cells 
because nonsense or missense mutations might alter cld mRNA levels80. Eight 
candidates were selected for co-expression with LPL in the cld/cld cell line derived and 
immortalized from mice hepatocytes and fibroblasts (MEF)81. Only one, Tmem112, 
rescued LPL and HL activity at levels comparable to heterozygous mice and as a 
consequence it was renamed to lipase maturation factor 1 (LMF1). Confirming this 
designation, EL activity in mouse-derived cld fibroblasts is rescued by transfection of 
LMF19. Reverse transcription-PCR in MEFs from cld mice revealed an insertion of a 
murine retrovirus resulting in a C-terminal truncation in LMF1 of 214 residues81. The C-
terminal domain of LMF1 contains a conserved domain of unknown function 1222 
(DUF1222) but co-localization of LMF1 with the ER-membrane bound calnexin shows 
that LMF1 resides in the ER. This localization is consistent with a role in protein folding 
in the ER in agreement with the Endo H data from cld mice and the site of LPL 
maturation. 
The topology for mouse and human LMF1 was elucidated using transmembrane 
prediction methods in combination with biochemical methods82. There are five 
transmembrane domains with the N-terminus is exposed to the cytosol and the C-
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terminus facing the ER lumen (Fig. 1.3). Consequently, C-terminal truncation variants of 
LMF1 were generated to study the role of the DUF1222 domain in LPL maturation as 
well as the interactions of LPL with the ER facing portions of LMF1 (loop A and C see 
Fig. 1.3). C-terminal truncations that entirely or partially remove the DUF1222 domain of 
LMF1 demonstrate these truncations still localize to the ER-lumen. However, neither 
construct restores LPL activity in the cld/cld cell line. Affinity purification of LPL or PL in 
complex with wild type (WT) or LMF1 variants shows that both lipases bind to loop C 
but not loop A. The studies with the C-terminal truncations of LMF1 confirmed the role 
of the DUF1222 domain in processing of LPL in the ER. Additionally, we learned that 
loop C does not confer LPL activity when it is in combination with loop A but it is 
necessary to bind LPL. It is likely that the loop C-LPL interaction is necessary for the 
folding role of the C-terminus of LMF1 on LPL. Lastly, affinity purification of EL and 
LMF1 complexes from HEK293 cells demonstrate that EL also physically interacts with 
LMF19 although it remains unknown if EL binds to loop C. In contrast to dimeric lipases, 
the activity of the monomeric PL is not reduced in cld cells, and PL does not bind to 
LMF19,83. Thus it has been suggested that LMF1 is important for the homodimerization 
of dimeric lipases.  
LMF1 mutations in humans are not lethal as they are for cld mice that die 2-3 
days after ingestion of dietary milk. Humans homozygous for LMF1 mutations can 
survive to adulthood without detection of severe hypertriglyceridemia as was the case of 
the first reported LMF1 mutation, Y439X81. The subject’s hypertriglyceridemia was not 
detected until 18 years of age with attacks of pancreatitis starting at age 27 despite a 
strict diet of 20 grams of total fat daily. The second nonsense mutation identified 
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localizes to residue W464. Similar to mice, the homozygous defect confers lipid 
accumulation whereas the subject’s son is heterozygous for the mutation and has 
normal TG levels. Functional analysis of both nonsense mutations in cld MEFs showed 
that the W464X mutation restores more LPL activity than the Y439X mutant, resulting in 
slightly better LPL secretion but not enough to prevent severe hypertriglyceridemia84.  
Even though three dimeric lipases are dependent on LMF1 for activity, we will 
focus our studies on LPL maturation.  LPL is the only dimeric lipase deficiency that is 
lethal in homozygous mice85 plus it is the rate-limiting enzyme for the hydrolysis of TG 
within the capillary lumen and several LPL mutations have been implicated in severe 
hypertriglyceridemia, atherosclerosis, and coronary artery disease in humans.  
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Figure 1.3 Schematic of LMF1 topology and summary of experimentally 
supported facts. 
LMF1 contains five transmembrane domains with loop A, loop C, and the C-terminus 
facing the ER lumen to promote dimeric lipase maturation. Human LMF1 is 567 amino 
acids (aa) long whereas mouse LMF1 is 574 aa long. The approximate size of each 
domain is: N-terminal 49 aa, loop A 56 aa, Loop C 71 aa, loop D 46 aa, and C-terminal 
188. The Y439X truncation removes 127 residues from human LMF1 while W464X 
removes only 103. 
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Despite the similarity of the phenotype from the cld mice with LPL and LMF1 
deficiency in humans, development of null LMF1 mice was needed to truly understand 
LMF1 deficiency in mice. The naturally occurring cld mutation in mice localizes to a 
variant of chromosome 17 known as the t haplotype, a region that contains mutations 
affecting several genes. As a result, the phenotype of the cld mice might include effects 
from other genes. Furthermore, the cld truncation variant of LMF1 expresses in HEK293 
cells and localizes in the ER. Thus, the allele could be hypomorphic, which would allow 
some expression of ~60% of LMF1. In agreement with cld mice, LMF1 null mice 
develop severe hypertriglyceridemia within 24 hrs after birth86. These mice also have a 
reduction in LPL and HL activities in the plasma. Their plasma lipoprotein profile 
demonstrates the high TG levels are due to accumulation of chylomicrons and VLDL; 
TG accumulation as well the impairment of lipase activity is not observed in 
heterozygous or WT littermates. Thus LMF1 null mice recapitulate the phenotype 
observed in cld mice confirming that the phenotype previously observed is indeed 
consequence of only LMF1 deficiency. Lastly, LMF1 is ubiquitously expressed but the 
null LMF1 mice demonstrate that LMF1 not needed for embryonic viability81,86. 
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Mutations associated with severe hypertriglyceridemia 
Severe hypertriglyceridemia is a condition characterized by plasma triglyceride 
levels greater than 1,000 mg/dL (>11.3 mmol/liter)87. LPL deficiency results in 
accumulation of CM and VLDL that leads to severe hypertriglyceridemia. LPL deficiency 
is an autosomal recessive disorder caused by loss of function mutations in the LPL 
gene. The frequency of LPL deficiency is 1 in half a million and it typically presents at 
childhood with abdominal pain, eruptive xanthomas, lipemia retinalis, and recurrent 
pancreatitis. Nearly 100 LPL mutations have been identified in humans. These 
mutations can abolish LPL’s catalytic function or prevent interaction with ApoCII, ApoAV 
or GPIHBP1 and hence result in severe hypertriglyceridemia88-90. Mutations in genes 
that interact with LPL also result in severe hypertriglyceridemia. These include ApoCII, 
ApoAV, GPIHBP1, and LMF181,89.  
In contrast to the great majority of LPL mutations found to date, population-based 
studies of LPL variants have revealed a cardioprotective effect for the nonsense mutant 
S447X. This mutation is found in 20% of the population where it is associated with 
reduced plasma TG and increased HDL cholesterol91,92. As discussed in the next 
section, this mutant is used as treatment for LPL deficiency. 
Current treatments for absence of LPL in the capillary lumen 
The usual treatment for people with LPL deficiency is a restricted low fat diet and 
the utilization of lipid lowering drugs like statins and fibrates. Statins are the main 
treatment of choice for reduction of LDL in individuals at high risk for atherosclerotic 
cardiovascular disease93. However, a recent study demonstrates that statin treatment is 
not sufficient to prevent coronary artery disease for individuals with TG levels >150 
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mg/dl94. Fibrates are ineffective for LPL deficiency treatment because they promote LPL 
expression and repression of ApoC-III through activation of the peroxisome proliferator-
activated receptors (PPAR-α)95. Additionally, a low fat diet does not eliminate disease 
progression and pancreatitis episodes. Gene therapy with intramuscular injections of 
the gain of function LPL mutation S447X has been shown to reduces plasma TG levels 
in clinical trials96. However, TG levels returned to base line after 18-31 months due to an 
immune response to the AAV1-capsid. A second clinical trial included 
immunosupressants. Twenty-six weeks post treatment, LPL protein levels were 
detected in 4 out of 7 samples while LPL activity was detected only in 397. Additionally, 
after 3-12 weeks of treatment, 50% of the subjects had a ≥40 reduction in plasma TG 
levels while two subjects had no improvement. More importantly, TG levels return to 
baseline 16-26 weeks post-treatment. Even though gene therapy with the LPL variant 
S447X was approved by the European Commission in 2012, the cost for therapy is over 
1 million dollars which is not cost effective considering the fleeting effects of the 
treatment98. A more effective treatment is needed for patients with LPL deficiency. 
Elevated TG levels and cardiovascular disease 
Additionally, elevated TG levels are associated with risk of cardiovascular 
disease99. Data from the American Heart Association shows that one third of adults in 
the US have borderline high lipid levels, and a further one third have high lipid levels or 
hypertriglyceridemia100. Thus understanding how LMF1 promotes LPL maturation may 
aid future drug development to treat hypertriglyceridemia. The intracellular pool of 
inactive and aggregated monomers of LPL destined for ER degradation could be 
rescued by pharmacological chaperones66. Pharmacological chaperones are 
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compounds that rescue proteins from degradation in the ER by serving as a folding 
template, restoring activity and trafficking pathways101,102. Treatment with 
pharmacological chaperones for LPL could prevent risk of cardiovascular disease due 
to high lipid levels. 
Summary  
Although LMF1 is necessary for maturation of all three dimeric lipases, several 
questions remain regarding the role of LMF1 in LPL maturation. How is LMF1 retained 
in the ER lumen? We know that only loop C and the C-terminus domain of LMF1 are 
known to bind or be necessary for LPL activity respectively. Would a truncation leaving 
these domains unperturbed be sufficient for LPL processing in the ER resulting in active 
and secreted lipase? Additionally, it is clear that LMF1 plays a role in the maturation of 
dimeric lipases. However, the mechanism by which it assists in this process is unclear. 
What is the role of LMF1 in tissues that do not express dimeric lipases and what are the 
substrates of LMF1 in those tissues? The remainder of this thesis addresses these 
questions. Chapter 2 works on the gaps left by the C-terminal truncations of LMF1. 
Instead we generated N-terminus truncations of LMF1 to determine the minimal 
domains of LMF1 necessary for secretion of LPL. Lastly, Chapter 3 describes our 
identification of interacting partners of LMF1 that assist in maturation of LPL and that 
can shed light on the role of LMF1 in LPL maturation. 
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 PURIFICATION, CELLULAR LEVELS, AND FUNCTIONAL DOMAINS CHAPTER 2:
OF LIPASE MATURATION FACTOR 11 
Introduction 
Lipoprotein lipase (LPL) plays a critical and complex role in lipid metabolism. LPL 
hydrolyzes triglycerides (TGs) from two classes of circulating lipoproteins, VLDLs and 
chylomicrons, in order to distribute free fatty acids to peripheral tissues. Biochemical 
deficiency of LPL activity is one well-established cause of hypertriglyceridemia, which is 
associated with increased risk of atherosclerosis, acute pancreatitis, and presence of 
metabolic syndrome103. Mutations in both LPL and its interacting partners can result in 
biochemical deficiency of LPL activity. Here we investigate how one of these interacting 
partners known as LMF1 promotes LPL activity. 
Deleterious mutations in the gene for LMF1 result in severe 
hypertriglyceridemia81,104. LMF1’s precise genetic location was only recently 
discovered81, but its role in promoting LPL activity is well established. Mice with a 
recessive mutation on chromosome 17 were severely deficient for the activity of LPL 
and the very closely related hepatic lipase (HL)77. This mutation was termed cld, for 
combined lipase deficiency77. Mice with homozygous disruptions in the LPL gene had 
phenotypes that were nearly indistinguishable from cld/cld mice (death within 48 hours 
of birth with extreme elevations of serum triglycerides85. However, the cld mutation 
                                            
1The work referenced in this chapter has been published in: Babilonia-Rosa MA and Neher SB. 
(2014) Purification, cellular levels, and functional domains of lipase maturation factor 1. 
BiochemBiophys Res Commun. 450,423-8. 
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clearly did not affect the LPL and HL structural genes, as these genes mapped to 
different chromosomes105. Furthermore, the amount of LPL protein present in tissues 
was not reduced, but its activity was106. LPL activity was reduced because the majority 
of the LPL was retained in the ER as inactive aggregates in cld/cld cells83. Recently, the 
cld mutation was mapped to a gene coding for an ER-resident, transmembrane protein, 
and renamed LMF1, for lipase maturation factor 181. Subsequently, LMF1 was found to 
be important for the activity of a third dimeric lipase, endothelial lipase9. 
Although LMF1 is vital for secretion of active, dimeric lipases, it is not clear how it 
promotes the exit of dimeric lipases from the ER. It is therefore important to determine 
which domains of LMF1 contribute to dimeric lipase maturation. Mapping studies of 
LMF1's domain architecture reveal that it has a total of five transmembrane domains 
with its N-terminus in the cytosol and its C-terminus in the ER lumen82. The loops 
connecting these transmembrane domains are labeled A-D and are diagramed in Figure 
1A. Recent data suggest that loop C and the C-terminus of LMF1 are important for 
dimeric lipase maturation82. The importance of LMF1's C-terminal, ER resident domain 
was established in studies of the original cld mutation and in patients with LMF1 
mutations. Two nonsense mutations in the C-terminal ER domain of LMF1 (Y439X and 
W464X) resulted in truncated variants that were unable to assist dimeric lipases in the 
maturation process81,104. Additionally, co-immunoprecipitation studies performed on C-
terminal LMF1 truncations showed that loop C is important for interaction with dimeric 
lipases82. Before this current study, nothing was known about the role, if any, of the N-
terminal portions of LMF1. 
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Here, we sought to determine which of LMF1’s domains are essential for its 
function and how LMF1 interacts with LPL by measuring the cellular levels of both 
proteins. To determine if the C-terminal portions of LMF1 were sufficient to promote 
dimeric lipase maturation, we made N-terminal LMF1 truncation variants. We show that 
these LMF1 truncations are properly localized and oriented in ER membrane. However, 
expression of these constructs in cld/cld cells show that the entire LMF1 protein is 
required for maturation of LPL. We generated a high-affinity, polyclonal antibody using 
purified LMF1. We found that endogenous LMF1 levels are very low, and each LMF1 
molecule promotes the maturation of at least 50 molecules of LPL.  
Experimental procedures 
Expression constructs 
Constructs for the expression of CD3δ-YFP and CFP-CD3δ107 and mCherry-
KDEL (mCh-KDEL)108 have been described. The coding sequence of human LPL was 
amplified from pCMV-SPORT6-LPL (Open Biosystems) with a C-terminal V5 epitope 
tag and inserted into the NheI and XbaI sites of pIRES-EGFP (Addgene). For LMF1 
variants, the cDNA for human LMF1 was obtained from Open Biosystems (ID 
100062174) and inserted into the BamHI/Xho1 sites of pcDNA5/FRT/TO with an 8x C-
terminal polyhistidine tag. The forward primer for TM3 (5’-tcccggattgtcctgtggggc-3’) and 
TM5 (5’-tcccggattgtcctgtggggc-3’) were selected based on computational models for the 
topology of human LMF182. Both LMF1 truncations included an N-terminal MHRRRS 
ER retention signal from human invariant chain isoform Iip33109 and an 8x C-terminal 
polyhistidine tag. To generate pFastbacLMF1, the coding sequence for human LMF1 
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was amplified with an added C-terminal polyhistidine tag and inserted into the Spe1 and 
Xba1 sites of pFastbac1 (Invitrogen).  
Cell lines, transfection, and media collection 
COS-7, cld/cld and cld/wt110 cell lines were maintained at a split ratio of 1:10 in 
Dubelcco’s modified Eagle’s medium, 10% fetal bovine serum, 1% 
penicillin/streptomycin, and 1% L-glutamine (complete medium). Transfections were 
performed with 2 mg of DNA and X-treme gene (Roche Applied Science) according to 
manufacturer’s instructions. COS-7 cells were transfected using Fugene 6 (Promega) 
with 0.3 mg of mCh-KDEL, 1.7 mg of LMF1 constructs, and 1 mg of CD3δ-YFP and 
CFP-CD3δ. Cells were transfected 24 hours after plating and harvested 24 h post-
transfection. For secretion experiments, the media of cld/cld or cld/wt cells was changed 
to complete media but with 1% FBS and 15 u/mL of heparin 3 hours prior collection, 600 
µL media was used per 9.5 cm2 well.  
Western blot analysis 
Cells were lysed 24 hours after transfection using lysis buffer (150 mM NaCl, 1% 
Triton X-100, 50 mM Tris pH 8). The pellets were re-suspended with 3X SDS loading 
dye diluted with 8M urea. Media, lysate, and pellet samples were separated using 12% 
SDS-PAGE. Proteins were transferred to PVDF (Millipore) and blocked with 5% nonfat 
milk in TBS-T. For LMF1 Westerns, chicken anti-LMF1 antibody was used at 1:10,000, 
AP-conjugated anti-chicken (Thermo Scientific) was used at 1:5000, and Westerns were 
developed using ECF reagent (GE Healthcare). Epitope tags were detected with anti-
His and anti-V5 antibodies diluted 1:5000 (both mouse, Thermo Scientific). Mouse anti-
GAPDH (Millipore) was used at 1:20,000, and HRP-conjugated anti-mouse (Southern 
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Biotech) was used at 1:20,000. Rabbit anti-progesterone receptor (PR, Santa Cruz) was 
used at a 1:100 dilution. HRP-conjugated secondary antibodies were used at 1:5000. 
Westerns were developed using ADVANSTA WesternBright reagent (Bioexpress).  
Indirect Immunofluorescence 
COS-7 cells were plated to 70% confluency on glass coverslips. Twenty-four 
hours post-transfection, the cells were fixed with 4% paraformaldehyde in PBS for 15 
min. Cells were washed three times with PBS then incubated for 10 min with 0.1% triton 
X-100 and 100 mM glycine. Coverslips were washed three times with PBS, then 
blocked with 2% BSA for 30 minutes, and incubate with anti-his antibody (1:200 in 2% 
BSA) for 1 hour at room temperature. Secondary antibody (Alexa Fluor 488-conjugated 
anti-mouse, Molecular Probe) was diluted 1:800 in 2% BSA and incubated for 1 hour at 
room temperature in darkness. DAPI (Sigma-Aldrich) was used at 0.8 mg/mL for 10 
minutes. After further washing in PBS, coverslips with cells were mounted facedown 
onto glass slides (Fisher) using ProLong Gold Antifade (Molecular Probes). Cells were 
examined at room temperature under a Zeiss LSM 710 confocal microscope with a 63X 
oil/1.4 Plan Apo.  
Protease protection assay (PPA) 
The PPA was performed as described111 with the following modifications. COS-7 
cells were permeabilized with 120 µM digitonin (Sigma Aldrich) for 1 min followed by 20 
µM trypsin (Sigma Aldrich) incubation for 1 or 2 min. Complete medium was added to 
stop trypsin cleavage. The cells were spun at 9000 RPM for 5 minutes, washed with 
PBS, and lysed with lysis buffer for 30 minutes. Samples were analyzed by Western 
blotting as above. LMF1 and GFP were detected with anti-his and anti-GFP (rabbit, 
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Abcam) antibodies, respectively, at 1:5000. HRP-conjugated secondary antibodies were 
used at 1:20,000. 
Protein purification 
LPL-V5 was purified essentially as previously described61. LMF1 was expressed 
in SF9 cells. Bacmids generated as per manufacture’s instructions (Invitrogen) were 
transfected into SF9 cells using Xtreme gene (Roche). Baculovirus was amplified for 
three passages and used to infect SF9 cells. Infected cells were harvested after 72 
hours, resuspended in Buffer 1 (20 mM Tris pH 7.5, 100 mM NaCl, and 5 mM β-
mercaptoethanol) with added complete protease inhibitor (Roche). Cells were lysed with 
2 passes through an EmulsiFlex (Avestin). Lysate was spun at 100,000 xg for 1 hour. 
The pellet was resuspended in Buffer 1 and dounced until in solution. Fos-Choline 12 
was added to 20 mM, the solution was rocked overnight at 4°C and then spun at 
100,000 xg for 1 hour. The supernatant was load onto Ni-NTA (Qiagen), washed with 
Buffer 1 plus 3 mM Fos-Choline 12, and eluted the same buffer plus 400 mM imidazole. 
Eluate fractions containing protein were loaded onto a MonoS column in Buffer 1 plus 3 
mM Fos-Choline 12 and eluted over 15 column volumes to Buffer 2 (20 mM Tris pH 7.5, 
1M NaCl, 1 mM DTT, 3 mM Fos-Choline 12). Select fractions were further separated on 
S200 in Buffer 3 (20 mM Tris pH 7.5, 100 mM NaCl, 1 mM DTT, 3 mM Fos-Choline 12, 
10% glycerol). Fractions were flash frozen on liquid nitrogen.  
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Antibody production 
 Antibodies against purified LMF1 were raised in chickens according to standard 
protocol (Covance) and purified as described112. 
Genomic PCR 
DNA was isolated from cld cell lines with DNeasy kit (Quiagen) according to 
manufactures directions. The primer sequences used to distinguish between WT LMF1 
and cld LMF1 have been described81.  
Results 
The C-terminus of LMF1 is not sufficient for dimeric lipase maturation 
The C-terminal, ER resident domain of LMF1 is necessary for efficient exit of LPL 
from the ER81,104. However, the importance of the N-terminal portions of LMF1 in LPL 
maturation is not known. To identify the minimal LMF1 construct that can support LPL 
maturation, we made two N-terminal truncations of LMF1 (Fig. 2.1A). To ensure that 
these truncation variants were properly targeted to and retained in the ER, we added a 
short, N-terminal motif from the human invariant chain isoform Iip33 previously shown to 
target an unrelated membrane protein to the ER109. This Iip33 segment replaced N-
terminal portions of LMF1 in two truncation constructs named TM3 and TM5 (Figure 
2.1A). TM5 is comprised of only the C-terminal ER domain whereas TM3 has this 
domain plus loop C, which was previously shown to be important for binding to LPL 82. 
These truncations allowed us to test the role of loop C and the C-terminus of LMF1 
independently. Full length (FL) LMF1, TM3 and TM5 all have C-terminal His tags for 
uniform detection, and all were transiently transfected in cld/cld cells. As expected, FL, 
TM3, and TM5 were detected by Western blot at 60, 43, and 27 kDa (Fig. 2.1B). TM5 
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was highly expressed and so 5-fold less protein was loaded to allow detection of the 
other LMF1 variants. No LMF1 was detected in the soluble fraction, showing that the 
truncation versions localize to the membrane as expected.  
Next, C-terminally V5-tagged LPL was co-expressed with each of the three LMF1 
constructs in cld/cld cells to determine the minimal domain of LMF1 sufficient for LPL 
maturation. Heparin was added to the media to induce release of LPL from the cell 
surface into the media. LPL is expressed in cells with all LMF1 constructs, as it is 
detected in the lysate and pellet fractions (Fig. 2.1C). However, LPL is only secreted 
when FL LMF1 is present (Figure 2.1C, media fraction). Taking into account that only 
1/5th of the TM5 pellet was loaded, there is more LPL in the pellets of TM3 and TM5 
than in the FL LMF1 pellet fraction. This suggests that when FL LMF1 is not present, 
LPL can’t fold properly and is not able to exit the ER, as shown for cells lacking 
LMF1113. Taken together, the release of LPL into the media only with FL LMF1 and the 
accumulation of LPL in the pellets when co-expressed with the TM3 and TM5 
truncations indicate that FL LMF1 is needed for the maturation process of LPL.  
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Figure 2.1 The N-terminal domain of LMF1 contributes to LPL maturation. 
A) A schematic of full length (FL) LMF1’s topology as well as both N-terminal 
truncations. The MHRRRS sequence was added as an ER retention signal. B) Western 
blots against the C-terminal His tag show that FL, TM3 and TM5 truncations are 
associated with the pellet fraction. Loading controls include GAPDH for soluble proteins 
in the lysate fraction and PR for membrane proteins. C) Western blots of the media 
fraction show that LPL-V5 is secreted in cld/cld cells co-expressing the FL, but not the 
TM3 or TM5, LMF1 constructs. In all panels, 1/5 as much of the TM5 was loaded to 
allow detection of the other constructs because TM5 was highly expressed.  
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Localization of LMF1 constructs by fluorescence microscopy 
To ensure that the N-terminal ER retention signal from Iip33 properly targeted 
both LMF1 truncation variants to the ER we tested for co-localization with an ER marker 
(mCh-KDEL) by immunofluorescence. COS-7 cells were co-transfected with LMF1, 
TM3, or TM5 and mCh-KDEL. Figure 2.2 shows that LMF1 co-localizes with mCherry-
KDEL. The merge of the two bottom panels of Fig. 2 shows that both LMF1 truncation 
variants co-localize with mCh-KDEL as well as FL LMF1 does. We can conclude that 
although TM3 and TM5 are not sufficient to promote LPL maturation, both truncations 
are present in the ER.   
32 
 
 
Figure 2.2 LMF1 truncation variants localize to the ER. 
Immunocytochemistry of the LMF1 variants (green) was compared to the ER marker 
mCh-KDEL (red) in COS-7 cells. All LMF1 constructs show perinuclear staining 
characteristic of the ER as is confirmed by co-localization with mCh-KDEL. Scale bars 
represent 20 µm. 
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Membrane topology of LMF1 constructs 
Truncation of the N-terminus of LMF1 could result in insertion of the protein into 
the ER with an incorrect orientation. We therefore performed a protease protection 
assay (PPA) to determine the orientation of the LMF1 truncations in the ER. In this 
assay, the plasma membrane is selectively permeablized with digitonin followed by 
trypsin treatment111. Trypsin will cleave membrane domains not protected within the 
lumen of organelles. COS-7 cells transfected with CD3δ-YFP (CD3δ with a YFP tag 
exposed to the cytosol) served as a positive control for trypsin cleavage (Fig. 2.3A, left 
panel). CD3δ with a CFP tag protected by the ER lumen (CFP-CD3δ) was a negative 
control to ensure that the organelles were preserved at the digitonin conditions used. 
Figure 3A shows complete loss of CD3δ-YFP signal within 2 minutes of trypsin 
exposure whereas incubation with digitonin alone does not result in YFP degradation. 
The right panel of Figure 2.3A shows no degradation of the 50 kDa CFP-CD3δ band, 
confirming that the assay conditions leave the ER membrane intact.  
We next tested if FL, TM3 and TM5 LMF1 were properly oriented in the ER. If 
these proteins have the correct topology, their C-terminal His-tags will be trypsin 
resistant. Unlike CFP-CD3δ, which has ER-protected CFP attached to a single 
transmembrane domain, we expected that LMF1 will show some cleavage products 
after trypsin treatment. Human LMF1 has 5 transmembrane domains with 16 cytosolic 
trypsin cleavage sites (PeptideCutter). Trypsin could cut LMF1 multiple times but only 
the products attached to the C-terminal His-tag will be detected. Following trypsin 
addition to cells expressing FL LMF1, we detect bands corresponding to both the full 
protein (60 kDa) and cleavage products. The cleavage products, ranging from 27 to 20 
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kDa, are likely due to the 7 trypsin sites in the last cytosolic loop of LMF1 (Fig. 2.3B, left 
panel).  After trypsin treatment uncleaved TM3 was present at 43 kDa in addition to 
lower molecular weight cleavage products (Fig. 2.3B, middle panel). For TM5 (Fig. 
2.3B, right panel); uncleaved TM5 appears at about 27 kDa. The band profile is not 
altered upon trypsin addition because no exposed cytosolic loops are expected in this 
construct. Retention of the majority of the signal from the His-tag following trypsin 
treatment indicates that TM3 and TM5 have their C-termini located in the ER. Thus, the 
Iip33 ER retention signal targets the LMF1 truncation constructs to the ER with the 
same membrane orientation as WT LMF1.   
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Figure 2.3 Topology of LMF1 truncations. 
A) A schematic of the CD3δ constructs used as positive and negative controls for 
trypsin cleavage, CD3δ-YFP and CFP-CD3δ respectively. The middle and right panels 
show the western blots for expression and the PPA. Lane 1 was mock (M) transfected, 
lane 2 shows untreated cells (U), lane 3 has 120 µM digitonin (D) addition for 3 minutes, 
and lane 4 has 20 µM of trypsin (T) for 2 minutes (after a 1 minute incubation with 
digitonin). Arrows indicate the FL version of each construct. B) Expression and PPA for 
WT LMF1 and the two truncation constructs. Lanes are labeled as in A.  
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Low level LMF1 expression is sufficient for LPL secretion.  
The relative expression levels of LMF1 mRNA have been compared across 
different tissue types, but little is known about LMF1 protein levels81. We generated an 
antibody against LMF1 to better understand its cellular levels. LMF1 was expressed in 
SF9 cells and purified to homogeneity as shown by coomassie staining and gel filtration 
(Fig. 2.4A). Purified protein was used to raise antibodies against LMF1 in chickens. 
This antibody could detect as little as 17.5 fmoles of purified LMF1 (Fig. 2.4B). 
However, Western blots using this antibody failed to detect a specific band for LMF1 in 
the cld/wt vs. cld/cld cells (Fig. 2.4B). When we transfected a plasmid containing LMF1 
under the control of a CMV promoter into the cells, a band at the expected molecular 
weigh of LMF1 appeared (Fig. 2.4B).  
Because we could not detect endogenous LMF1 in cld/wt cells, we wanted to 
ensure that both cell lines had the expected genotype. We confirmed the correct 
genotype of these cells by analysis of the genomic DNA. Genomic DNA was harvested 
and tested by PCR for insertion of the murine endogenous retrovirus into intron 7 of 
LMF1, which defines the cld mutation (Fig. 2.4C)81. Bands of the expected size were 
observed (Fig. 2.4C) indicating that LMF1 is present in the cld/wt but not the cld/cld 
cells, as expected.  
We cannot report the exact number of LMF1 molecules per cell, but can calculate 
an upper limit. The assays in figure 4B used 1 x 104 cells. Additionally, the membrane 
fraction of a greater number (1 x 106) of cld/cld and cld/wt cells was harvested, 
solubilized, and probed for LMF1 (data not shown). Based on these cell counts and the 
detection limit of our antibody, we can conclude that there are less than 10,000 
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molecules of LMF1 per cell, a relatively low expression level. A large-scale proteomics 
analysis of mammalian cells indicates that approximately 75% of proteins are expressed 
at higher levels114,115. Indeed, whereas LMF2 was identified in this analysis, LMF1 was 
not114,115. We next quantified the amount of LPL-V5 secreted into the media per cell 
using purified LPL-V5 as a standard (Fig. 2.4D). These experiments revealed that, over 
a 3-hour period, approximately 50,000 molecules of LPL were secreted/cell. Thus, each 
molecule of LMF1 can promote the maturation of 50 or more molecules of LPL.   
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Figure 2.4 LMF1 purification and cellular levels. 
A) Gel filtration trace of purified LMF1 shown with a coomassie stained gel. B) Western 
blot showing that an antibody raised against LMF1 can detect as little as 17.5 fmole of 
the purified protein. Cells are mock transfected (M) or transfected with a plasmid 
expressing LMF1. PR is a loading control for the pellet fraction. Arrows indicate both PR 
isoforms. C) Western blot for quantification of LPL released from cld/wt cells. D) LPL is 
better secreted from cld/wt than cld/cld cells, as expected. E) Top is a schematic 
showing oligos (D, E, F) used to test for the insertion of the murine endogenous 
retrovirus into intron 7 of LMF1. PCRs, below, show that cld/wt and cld/cld cells have 
the expected genotype.   
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Discussion  
Previous studies on LMF1 have focused on the C-terminus. In patients with 
defective LMF1, mutations are located in the C-terminus and in vivo co-IP’s show that 
loop C of LMF1 binds to LPL81,82,104. Based on these findings, we hypothesized that 
LMF1’s C-terminus is not sufficient for the maturation of dimeric lipases but the C-
terminus in combination with loop C would promote lipase maturation. To test this 
hypothesis, we made truncations of LMF1 starting from the N-terminus. Because LPL 
must be properly folded to enter the secretory pathway83, we tested LPL secretion into 
the media in cells expressing only the N-terminally truncated variants of LMF1. These 
data show that FL LMF1 is required for the maturation process of LPL.  Because the ER 
retention signal of LMF1 is not known, we used the ER retention signal of Iip33 to 
ensure ER localization of the truncated variants. To demonstrate that the TM3 and TM5 
LMF1 truncations did not compromise ER localization and the luminal orientation of the 
C-terminus, we co-localized LMF1 with an ER marker and performed a protease 
protection assay. The results of these combined experiments demonstrate that TM3 and 
TM5 LMF1 have the same localization and topology as FL LMF1. However, they cannot 
promote the maturation of LPL, indicating that the N-terminus has an important, but 
unknown function. 
We generated a polyclonal antibody to measure LMF1 protein levels. This 
antibody was very sensitive but could not detect endogenous levels of LMF1. We 
calculated that there are at most 10,000 molecules of LMF1 per cell, and that each 
molecule of LMF1 assisted in the maturation of at least 50 molecules of LPL during a 3-
hour period. These data give some hints at LMF1 function. Because LMF1 protein is 
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present at a relatively low level compared to general chaperones like GRP78, calnexin, 
and calreticulin, which are present at over 1,000,000 molecules per cell, it must perform 
a specialized function114,115. Additionally, LMF1 has a catalytic role because each 
molecule can efficiently promote the maturation of multiple molecules of LPL.  
It is widely accepted that LMF1 is required for maturation of dimeric lipases, but it 
is not known if LMF1 coordinates the activities of other interacting partners. FL LMF1 is 
required for lipase maturation, but only loop C and the C-terminus have a known role. 
This suggests that other domains of LMF1 could interact with binding partners required 
for lipase maturation. Supporting this idea, we were unable to detect a strong, direct 
interaction between purified LPL and LMF1 in vitro (data not shown). Additionally, real 
time-PCR analysis shows that LMF1 mRNA is expressed at higher levels in tissues that 
lack dimeric lipases, such as the pancreas and testis, compared to tissues expressing 
dimeric lipases81. Future studies will be needed to determine if LMF1 requires 
interacting partners to promote lipase maturation as well as if LMF1 has a role other 
than lipase maturation in other tissues.  
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 NOVEL BINDING PARTNERS OF LMF1 SUGGEST A ROLE IN CHAPTER 3:
OXIDATIVE FOLDING IN THE ER 
Introduction  
LPL is a secreted, dimeric lipase that hydrolyzes triglycerides present in the 
lipoproteins VLDL and chylomicrons. Because LPL is rate limiting for clearance of 
triglycerides from the plasma, LPL deficiency results in severe hypertriglyceridemia. As 
a secreted protein, LPL transits the ER where its two N-linked glycans and five disulfide 
bonds are processed. LPL also requires a specialized factor, LMF1, for proper folding 
and exit from the ER81. When LMF1 is absent, LPL forms disulfide-bonded aggregates 
in the ER, resulting in a phenotype similar to LPL deficiency83,116. LMF1 assists in the 
maturation of not only LPL but also the related, dimeric lipases endothelial lipase (EL) 
and hepatic lipase (HL)81. Pancreatic lipase, a sequence-related, but monomeric lipase, 
does not require LMF1.  
LMF1 is a ER-resident membrane protein that has 5 membrane-spanning 
domains, resulting in two loops and a large C-terminal domain in the ER lumen117. 
Known deleterious mutations that prevent LPL secretion are located in the C-terminal, 
ER resident domain81,84. In vivo pull down experiments showed that loop C interacts 
with LPL117. Finally, our N- and C–terminal truncation experiments show that every ER 
resident loop of LMF1 is required for LPL maturation118. 
LPL has ten cysteines conserved across species that are known to form five 
disulfide bonds1,4. Three of these disulfide bonds are critical for the activity of LPL 
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(C216/C239, C264/C275, C278/C283)73. Protein folding and quality control in the 
endoplasmic reticulum (ER) requires not only oxidation of thiols to form disulfide bonds 
but also reduction of disulfide bonds to facilitate the degradation of misfolded proteins. 
Members of the disulfide isomerase (PDI) family mediate this thiol-disulfide exchange in 
eukaryotes119. Although glutathione powers the reduction of disulfide bonds120, 
eukaryotes have long been hypothesized to utilize another source of reducing 
equivalents. The bacterial transmembrane electron transporter, DsbD transfers two 
electrons from thioredoxin to the protein disulfide isomerase DsbC for formation of 
nonconsecutive disulfide bonds121. DsbC must remain in a reduced state to initiate 
isomerization and DsbD is required to maintain DsbC in a reduced state122.  
In order to understand how LMF1 promotes LPL maturation we took two 
approaches. First, we developed lipase chimeras with the LMF1-independent PL to 
determine what region of LPL interacts with LMF1. The chimeras revealed that the C-
terminus of LPL binds to LMF1 and this interaction is important for dimeric lipase 
secretion. Second, we utilized crosslinkers and proteomics to identify binding partners 
of LMF1. We uncovered a number of ER-resident oxidoreductases as well as 
thioredoxin (TRX), a cytosolic protein. We further show that TRX, ERp44, and ERdj5 
bind to LMF1 in the absence of a crosslinker. In combination these data suggest that 
LMF1 acts like the bacterial protein DsbD, which shuttles electrons across the 
periplasmic membrane to DsbC.  
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Experimental procedures 
Expression constructs 
Constructs for wild type LMF1 and the C-terminal truncations with an 8X C-
terminal polyhistidine tag were previously described123. Site directed mutagenesis of 
LMF1-His was employed to obtain C to A mutations via two single-primer reactions in 
parallel124.  The orthogonal pair of suppressor tRNA (B. stearothermophilus) and tRNA 
synthetase (S. cervisiae) for photocrosslinking were provided by P. Schultz (The 
Scripps Research Institute)125. AvrII and BsrGI sites were used to remove GFP from the 
pSWAN-GFP37TAG and insert LMF1 (Open Biosystems) with an 8X C-terminal 
polyhistidine tag. The amber codon was incorporated in the pSWAN-LMF1 in residue 
F262 using site directed mutagenesis. Human LPL was excised from pCMV-SPORT6-
LPL (Open Biosystems), a C-terminal V5 tag was added, and it was inserted into a 
pcDNA5⁄FRT vector (Thermo Fisher Scientific) using HindIII/BcII sites. To clone the 
lipase chimeras, the pcDNA5⁄FRT vector was cut with HindIII/Bcl1 and LMF1 was 
inserted with an N-terminal polylinker containing XmaI, Pme1, and Cla1 sites. The 
Pme1 and Cla1 sites were used to insert an IRES from the vector pIRES-EGFP 
(Addgene) into pcDNA5⁄FRT. Human LPL or PL with a C-terminal V5 tag were inserted 
using NheI/Xho1 or NheI/Xma1 respectively. PCR-driven overlap extension126 was used 
to create a chimera containing the N-terminal of LPL with the C-terminal of PL (LPL/PL) 
and the reverse construct (PL/LPL). Both chimeras contained a C-terminal V5 tag and 
were inserted in the modified pcDNA5⁄FRT. To make the plasmid for expression of 
TXNIP, the cDNA sequence of human TXNIP was synthesized as a GBlock by IDT. It 
was digested using A and B enzymes and inserted in pCNDA5/FRT.  
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Cell lines, transfection, and media collection 
HEK 293 Flp-In™ (Thermo Scientific) cells were transfected with LPL-His or 
LMF1-His using Fugene 6 (Promega) and selected with 200 µg/mL of hygromycin. 
Regular HEK 293 cells were transiently transfected with Fugene 6 and 1 µg of DNA for 
LMF1-His and the respective lipase construct for the DSP crosslinking experiment in 
Figure 3.1C. Transfection of cld/cld cells on six well plates was performed with 2 µg of 
DNA and X-treme Gene HP127 according to manufacturer’s instructions. All cell lines 
were maintained in Dubelcco’s modified Eagle medium with 10% fetal bovine serum, 
1% penicillin/streptomycin, and 1% L-glutamine (complete media). 
siRNA Knockdowns 
siRNA transfections were performed with 20 nM of RNA oligonucleotide and 7 µL 
of Lipofectamine RNAiMax (Life Technologies) per six-well plate and samples were 
collected 48 hours post-transfection. Validated Silencer Select siRNAs were obtained 
from Life Technologies: negative control No. 1 (4390843), ERp44 (s22965), PDI (s439), 
ERp72 (s18446), UGGT1 (132932), UGGT2 (112074), and ERdj5 (132773). 
Knockdown was quantitated using a ChemiDoc MP Imaging System from Biorad and 
quantitated using Image Lab Software. The percent of remaining gene expression was 
calculated with the following formula: 
((Candidate/GAPDH)/(NC/GAPDH))*100. To obtain the percent knockdown = 100 - 
percent remaining expression. 
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Crosslinking and pull down assays 
For pull down assays of LMF1-His from HEK Flp-In stable cell lines, two T-75 
flasks per condition were seeded with 7.5 X 106 cells. LMF1-His expression was 
induced with 2 µg/mL tetracycline the next morning. The next day, cells were 
trypsinized, washed with 1X PBS, crosslinked with 2 mM DSP (ProteoChem) with 
agitation for 30 minutes at room temperature, and quenched with 150 mM Tris pH 8. 
The cells were lysed with by douncing in buffer 1 (250 mM NaCL, 10 mM Tris pH 8, and 
1 mM PMSF). Following centrifugation for 20 minutes at 13,000 RPM, the pellets were 
re-suspended by douncing with 1.4 mL of buffer 1. Lysates were incubated overnight 
with agitation and the addition of 20 mM fos-choline 12 (Anatrace). After centrifugation 
as above, 5% glycerol and 40 mM imidazole were added to the supernatant as well as 
Ni-NTA agarose beads (Qiagen). Binding was allowed for an hour at 40C with agitation. 
The beads were washed 3X with 4 mL of buffer 2 (1M NaCl, 10 mM Tris pH 8, 3 mM 
fos-choline 12, 5% glycerol, 40 mM imidazole, and 1 mM PMSF) in 11 mL poly-prep 
chromatography columns (Bio-Rad). LMF1 complexes were eluted with buffer 3 (250 
mM NaCL, 10 mM Tris pH 8, 3 mM fos-choline 12, 400 mM imidazole, and 1 mM 
PMSF). Eluate fractions were loaded on 8% SDS-PAGE, transferred to PVDF (Bio-Rad) 
for 75 minutes at 100V, and blocked with 5% nonfat milk or BSA.  
IP’s of LPL-His from HEK Flp-In stable cell lines were carried out similarly. 
Purification LMF1-His with lipases were carried out similarly but at a smaller scale. Cells 
were seeded at 6.5 X 105 cells per well of 6 well plates (Denville); 3 wells were 
combined per condition and Fugene 6 or X-treme Gene HP were used, respectively.   
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For photocrosslinking with pBpa, HEK 293 Flp-In™ stably expressing LPL-V5 
were plated in six-well plates at 10.5 X 105 cells per well; four wells were utilized per 
sample. The next day, 1 µg of pBpa plasmid or LMF1-amber construct were transfected 
with Fugene 6. After 24 hours, the media was replaced with media containing 2 µg/mL 
of tetracycline, 0.5 mM pBpa (Chem-Impex International), and 0.3% of DMSO. Control 
wells lacked pBpa but contained 0.3% of DMSO. Cells were grown with pBPA for 24 
hours. The media was changed to 1X PBS and the cells were kept on ice and 
crosslinked with a UV lamp at a wavelength of 365 nm for 30 minutes at 2.5 cm from the 
lamp. LMF1 was purified from cells as described above.  
Lipase secretion 
HEK 293 Flp-In stables expressing lipase constructs were induced with 2 ug/mL 
of tetracycline 24 hrs before media collection. Three hours before media collection, 
lipase secretion was promoted by addition of 600 µL of DMEM with 1% FBS and 15 
u/mL of heparin per 9.5 cm2 well. For cld/cld MEFs, lipase secretion was promoted 24 
hrs post-transfection. Samples from lipase secretion experiments were separated using 
12% SDS-PAGE.  
Antibodies  
The epitope tag of LMF1 was detected with an anti-His antibody (1:5,000 AbD 
Serotec). PDI, ERp72, and ERp44 antibodies were obtained from Cell Signaling, used 
at 1:1,000 in 5% BSA, and with HRP-conjugated anti-rabbit (Southern Biotech) at 
1:5,000. UGGT1, UGGT2, ERdj5, TRX and TXNIP antibodies were obtained Abcam; 
used at 1:500, 1:1,000, 1:500, 1:1,000, and 1:600 respectively in 5% BSA with HRP-
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conjugated anti-mouse or rabbit antibodies from Southern Biotech. Mouse anti-V5 
antibody from Bio-Rad was diluted 1:5,000.  
Mass Spectrometry 
Gel slices containing purified LMF1 with pBPA or DSP-crosslinked binding 
partners were delivered to the Duke Proteomics facility for analysis by mass 
spectrometry. Coomassie stained SDS-PAGE bands were subjected to standardized in-
gel trypsin digestion (http://www.genome.duke.edu/cores/proteomics/sample-
preparation/documents/In-gelDigestionProtocolrevised.pdf). Extracted peptides were 
lyophilized to dryness and resuspended in 12 uL of 0.2% formic acid/2% acetonitrile. 
Each sample was subjected to chromatographic separation on a Waters NanoAquity 
UPLC equipped with a 1.7 µm BEH130 C18 75 µm I.D. X 250 mm reversed-phase 
column.  The mobile phase consisted of (A) 0.1% formic acid in water and (B) 0.1% 
formic acid in acetonitrile.  Following a 3 µL injection, peptides were trapped for 3 min 
on a 5 µm Symmetry C18 180 µm I.D. X 20 mm column at 5 µl/min in 99.9% A.  The 
analytical column was then switched in-line and a linear elution gradient of 5% B to 40% 
B was performed over 30 min at 400 nL/min. The analytical column was connected to a 
fused silica PicoTip emitter (New Objective, Cambridge, MA) with a 10 µm tip orifice and 
coupled to a QExactive Plus mass spectrometer (Thermo) through an electrospray 
interface operating in a data-dependent mode of acquisition. The instrument was set to 
acquire a precursor MS scan from m/z 375-1675 with MS/MS spectra acquired for the 
ten most abundant precursor ions.  For all experiments, HCD energy settings were 27v 
and a 120 s dynamic exclusion was employed for previously fragmented precursor ions. 
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Raw LC-MS/MS data files were processed in Proteome Discoverer (Thermo 
Scientific) and then submitted to independent Mascot searches (Matrix Science) against 
an SwissProt database (Human taxonomy) containing both forward and reverse entries 
of each protein (20,322 forward entries).  Search tolerances were 5 ppm for precursor 
ions and 0.02 Da for product ions using trypsin specificity with up to two missed 
cleavages.  Carbamidomethylation (+57.0214 Da on C) was set as a fixed modification, 
whereas oxidation (+15.9949 Da on M) and deamidation (+0.98 Da on NQ) were 
considered dynamic mass modifications. All searched spectra were imported into 
Scaffold (v4.3, Proteome Software) and scoring thresholds were set to achieve a 
peptide false discovery rate of 1% using the PeptideProphet algorithm. 
NEM Modification 
HEK293 cells stably expressing LMF1 variants were seeded in a T75 flask at 5 
x106 cells. LMF1 expression was induced overnight with 2 µg/mL tetracycline. Cells 
were harvested, washed with PBS and precipitated with 10% TCA. The DTT treated 
control cells were first treated with 10 mM DTT for 10 minutes. Samples were spun for 
10 minutes at 40C in a microcentrifuge at 14,000xg, washed with ice cold acetone and 
resuspended with a mechanical douncer in 2% SDS, 50 mM Tris pH 7.4, 80 mM NEM. 
The DTT control sample was not treated with NEM. Samples were incubated at 370C for 
30 minutes, then denatured at 800C for 10 minutes. Samples were diluted 10x in Triton 
Buffer (2% triton, 50 mM Tris pH 8, 150 mM NaCl), cleared by centrifugation, and 
incubated with 200 µLs Ni-NTA resin. Samples were washed and purified as per the 
crosslinking assays, except that Triton buffer with 10 mM Imidizole was used for 
washing and Triton Buffer with 400 mM Imidizole was used for elution.  
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BSO, DTT, and tunicamycin sensitivity 
To assess cell sensitivity to buthionine sulphoximine (BSO), DTT and 
tunicamycin, first 1x105  cld/cld or cld/wt were plated in a 6-well plate. The next day 
either a buffer control, 10 mM L-BSO, 2.5 µg/mL tunicamycin or 5 mM DTT was added. 
After 24 (tunicamycin or BSO) or 12 (DTT) hours of treatment, cells were removed from 
the plate with trypsin, stained with trypan blue and live cells were manually counted 
using a hemocytometer. 
Results 
LMF1 Binds to the C-terminus of LPL 
To determine the LMF1 binding site in LPL we generated two LPL-PL chimeras. 
These chimeras are diagramed in Figure 3.1A. The PL-LPL chimeras consist of the N-
terminal domain of PL fused to the C-terminal domain of PL, whereas the LPL-PL 
chimera is comprised of the N-terminal domain of LPL fused to the C-terminal domain of 
LPL. Both chimeras, as well as the WT LPL and PL controls, have C-terminal V5 
epitope tags for uniform detection. As shown in Figure 3.1B, all of the lipase constructs 
are stably integrated into HEK293 cells under the control of a tetracycline inducible 
promoter. All of the proteins express, as shown in the lysate panel. However, only PL, 
LPL, and PL/LPL are secreted. Each variant was co-expressed with His tagged LMF1, 
crosslinked with the amine reactive crosslinker dithiobis-succinimidyl propionate (DSP), 
and affinity purified via LMF1’s His tag to detect interacting lipase constructs. Western 
blots showed that PL/LPL but not LPL/PL binds LMF1 (Fig. 3.1C). Thus, LMF1 
recognizes an element in the C-terminal β-sandwich domain of LPL. 
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Figure 3.1 LMF1 binds to LPL through its C-terminus. 
A) Schematic of lipase constructs. Human LPL has 475 residues while PL has 465. The 
PL/LPL chimera contains residues 1-341 of the N-terminus of PL and 329-475 of the N-
terminus of LPL. Respectively, the LPL/PL chimera contains residues 1-328 of LPL and 
342-465 of PL.  B) PL/LPL but not LPL/PL is secreted from cells. Tetracycline was 
added to induce lipase expression in HEK 293 FRT cells with stably integrated lipase 
constructs. Lipase secretion was induced with heparin. Lipase variants present in the 
media, lysate and pellet fraction were detected via their C-terminal V5 tags. C) PL/LPL 
but not LPL/PL is crosslinked to LMF1. LMF1-His was transiently transfected in HEK 
293 FRT cells stably expressing a lipase constructs. The crosslinker DSP was added, 
and LMF1 and associated proteins were purified via LMF1’s his tag. Panel 3 shows that 
only LPL and PL/LPL were detected in a complex with LMF1. The data for Figure 3.1C 
was provided by Lindsey J. Broadwell. 
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Identification of novel LMF1 binding Partners 
To better understand LMF1’s function we next set out to determine which 
proteins it interacts with in the cell. We used two crosslinking reagents to covalently link 
LMF1 and its partners during extraction from the membrane. DSP is a homobifunctional, 
amine reactive crosslinker with a cleavable disulfide bond in its spacer arm. We also 
used a method for site-specific incorporation of an artificial amino acid into LMF1128. In 
this system, an orthogonal tRNA and aminoacyl-tRNA synthetase pair incorporates an 
unnatural amino acid into LMF1 at a nonsense codon in a position of our selection. We 
used the artificial amino acid p-benzoylphenylalanine (pBpa), which crosslinks to nearby 
proteins when UV light is applied to the cells129.  
For DSP crosslinking, HEK293 cells stably expressing LMF1-His under the 
control of a tetracycline-inducible promoter were treated with crosslinker, and LMF1 was 
purified as we have previously described118. In Figure 3.2A a Western blot shows the 
increase in intensity of a 150 kDa band (asterisk) when LMF1 was induced with 
tetracycline and crosslinked with DSP. After the crosslinks were released, new bands 
representing LMF1 binding partners appeared in a gel stained for total protein (Fig. 
3.2B, asterisks). These bands were identified by LC-MS/MS at the Duke Proteomics 
Facility. For pBpa crosslinking, we used HEK293 cells transiently transfected with a 
plasmid bearing the orthogonal tRNA and aminoacyl-tRNA synthetase and a plasmid 
containing LMF1 with an amber codon and a C-terminal His-tag130. We purified LMF1 
and bound proteins, performed Western blots and identified robust interactions as 
shown by the multiple, higher molecular weight bands reacting with anti-His antibody 
(Fig. 3.2C, pBPA panel). Higher molecular weight bands can also be seen in the gel 
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stained for total proteins (Fig. 3.2D, asterisks). We excised these bands and sent them 
for protein identification by LC-MS/MS. The corresponding gel region of a sample 
without added pBpa served as a negative control. 
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Figure 3.2 Identification of new LMF1-interacting partners. 
A) Western blot of LMF1-partners after DSP crosslinking and affinity tag purification 
using LMF1’s C-terminal His tag. Tetracycline induces LMF1 expression. Loading dye 
with 50mM DTT was used to break the disulfide bonds between LMF1 and its 
interacting partners. LMF1 complexes are labeled with asterisks and an arrow points to 
FL LMF1. B) SYPRO orange protein stain of DSP crosslinked samples. Samples 
without tetracycline but with DSP and DTT, and with tetracycline, DSP and DTT were 
sent for LC MS/MS. C) and D) Western blot and SYPRO orange stained gel of LMF1-
partners after pBpa photo-crosslinking and affinity tag purification. The DMSO panel 
does not include pBpA and serves as a negative control. pBpa was added to the 
second sample so LMF1 complexes can be detected. Fractions were eluted with 
increasing concentrations of imidazole. 
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Over 300 proteins in total were identified in the two samples. We selected 
candidates identified with 95% or greater confidence with more peptides identified in the 
LMF1-containing sample than a control sample. Additionally, for pBpa the predicted 
molecular weight of the LMF1-candidate protein complex had to fall within or exceed the 
molecular weight range corresponding to LMF1 plus the molecular weight of the 
candidate. For both crosslinkers, we focused on proteins annotated as residing in the 
ER. Tables 3.1 and 3.2 list protein candidates that meet these criteria for DSP and 
pBpa respectively. Of note, we found SEL1L, a known LMF1-interacting protein, through 
our DSP crosslinking131. Additionally, in agreement with a proteomics study that isolated 
interacting partners of hepatic lipase, we found proteins associated to the 
calnexin/calreticulin system, Bip, protein disulfide isomerase A3 (ERp57), and proteins 
involved in ERAD which are highlighted in bold in Tables 3.1 and 3.2132.  
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Table 3.1 Mass spectrometry candidates from DSP crosslinking. 
 
Protein Function 
Unique 
Peptides 
% 
Coverage 
tet/ 
notet 
78 kDa glucose-
regulated protein 
(GRp78 or Bip) 
Protein folding and ERAD 7 13 23/8 
Calnexin 
Assist protein assambley or 
ER-retention of missfolded 
proteins. 
6 12 22/9 
Neural aplha-
glucosidase AB 
(GANAB) 
Cleavage of the 2 innermost 
glucose residues of 
oligosaccharide from 
immature glycoproteins 
11 18 19/11 
UDP 
glucose:glycoprotein 
glucosyltransferase 1 
(UGGT1) 
Reglucosidates 
glycoproteins with minor 
folding defects. 
6 6 17/6 
Tanslocation protein 
SEC63 homolog 
Translocation of proteins to 
the ER. 8 16 15/8 
Lipase maturation 
factor 1 (LMF1) 
Nessesary for the 
maturation of dimeric 
lipases in the ER. 
3 6 14/4 
Transitional 
endoplasmic reticulum 
ATPase (TER 
ATPase) 
Involved in the formation of 
the transitional ER, 
fragmentation of Golgi 
stacks and ERAD. 
9 13 13/9 
Sarcoplasmic/endopla
smic reticulum calcium 
ATPase 2 (ATP2A2) 
Translocation of calcium 
from the cytosol to the 
sarcoplasmic reticulum 
lumen. 
6 8 12/6 
Mannosyl 
oligosaccharide 
glucosidase (MOGS) 
Cleaves distal glucose from 
mannosyl-oligosaccharide 
of glycoproteins 
3 5 7/3 
Protein disulfide 
isomerase A3 
(ERp57 or PD1A3) 
Catalyzes rearrangement of 
disulfide bonds. 4 9 6/4 
Extended 
synaptotagmin-2 (E-
Syt2) 
Tethers ER to cell 
membrane. 3 4 6/3 
ER membrane protein 
complex subunit 1 
(EMC1) 
Protein folding 4 7 4/0 
DnaJ homolog 
subfamily C member 
10 (DNAJC10 or 
ERdj5) 
ER disulfide reductase 
involved in disulfide 
rearrangement and 
degradation of missfolded 
proteins. 
3 5 3/3 
Dolichyl-
diphosphooligosaccha
Subunit of the N-
oligosaccharyl transferase 1 2 3/1 
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Protein Function 
Unique 
Peptides 
% 
Coverage 
tet/ 
notet 
ride protein 
glycosyltransferase 
subunit 1 (RPN1) 
(OST) complex which 
catalyzes the transfer of a 
high mannose 
oligosaccharide to 
glycosilated proteins. 
Protein disulfide 
isomerase A4 (ERp72 
or PDIA4) 
Catalyzes rearrangement of 
disulfide bonds. 3 6* 3/0 
Glucosidase 2 subunit 
beta (GLU2B) N-glycan processing 3 7 3/0 
Protein disulfide 
isomerase (PDIA1) 
Catalyzes the formation, 
breakage and 
rearrangement of disulfide 
bonds. 
2 8 2/2 
UDP 
glucose:glycoprotein 
glucosyltransferase 2 
(UGGT2) 
Reglucosidates 
glycoproteins with minor 
folding defects. 
1 1 2/0 
Protein sel-1 homolog 
1 (Sel1L) 
Involved in ER-associated 
degradation (ERAD) 1 3 1/0 
Protein disulfide 
isomerase A6 (ERp5 
or PDIA6) 
Catalyzes rearrangement of 
disulfide bonds. 1 3 1/1 
Coatomer subunit 
beta (COPB1) 
Essential for the retrograde 
Golgi-to-ER transport of 
dilysine-tagged proteins 
1 1 1/0 
Exostosin-2 (EXT2) Protein glycosilation 1 1 1/0 
Thioredoxin Protein reduction by thiol-disulfide exchange. 1 9 2/1 
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Table 3.2 Mass spectrometry candidates from pBpa crosslinking. 
 
    Bottom Top 
Protein Function 
Unique 
Peptides 
% 
Coverage 
pBpa/ 
DMSO 
pBpa/ 
DMSO 
Endoplasmin Protein folding and ERAD. 7 10 7/0 7/1 
Protein disulfide 
isomerase A4 
(ERp72 or PDIA4) 
Catalyzes 
rearrangement of 
disulfide bonds.  
2 5  2/0 
78 kDa glucose-
regulated protein 
(GRp78 or Bip) 
Protein folding and 
ERAD 6 16 14/6 9/4 
Dolichyl-
diphosphooligosacch-
aride protein 
glycosyltransferase 
subunit 1 (RPN1) 
Subunit of the N-
oligosaccharyl 
transferase (OST) 
complex which 
catalyzes the transfer 
of a high mannose 
oligosaccharide to 
glycosilated proteins.  
3 6  3/0 
Calnexin 
Assist protein 
assambley or ER-
retention of 
missfolded proteins. 
1 3 1/1 1/1 
Lipase maturation 
factor 1 (LMF1) 
Nessesary for the 
maturation of dimeric 
lipases in the ER. 
3 6 10/3 9/2 
Glucosidase 2 
subunit beta (GLU2B) Glycan processing 3 6  3/0 
Protein disulfide 
isomerase (PDIA1) 
Catalyzes the 
formation, breakage 
and rearrangement of 
disulfide bonds. 
5 11 5/0 6/0 
Protein disulfide 
isomerase A3 
(ERp57 or PD1A3) 
Catalyzes 
rearrangement of 
disulfide bonds.  
5 10 5/0 7/0 
ERO1-like protein 
alpha (Ero1α) Oxidoreductase 1 3 1/0 2/0 
Zinc transporter 
SLC39A7 
Zinc transport from 
the endoplasmic 
reticulum/Golgi 
apparatus to the 
cytosol. 
2 3  2/0 
Calreticulin 
 Chaperone that 
promotes folding, 
oligomeric assembly 
and quality control in 
the ER. 
2 5 2/0 3/0 
Protein disulfide Catalyzes 1 3  1/0 
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    Bottom Top 
Protein Function 
Unique 
Peptides 
% 
Coverage 
pBpa/ 
DMSO 
pBpa/ 
DMSO 
isomerase A6 (ERp5 
or PDIA6) 
rearrangement of 
disulfide bonds.  
ER resident protein 
44 (ERp44) 
Oxidative protein 
folding. 2 5  2/0 
Serpin H1 Chaperone that binds to collagen. 2 5 2/0  
Peptidyl-prolyl cis-
trans isomerase B 
(PPIaseB) 
Catalyzes the cis-
trans isomerization of 
proline.  
2 9 2/0 4/0 
Ras related protein 
Rab-1A 
RAB1A regulates 
vesicular protein 
transport from the ER 
to the Golgi and on to 
the cell surface 
3 18 3/0  
Peptidyl prolyl cis-
trans isomerase A 
(PPIA) 
Catalyzes the cis-
trans isomerization of 
proline.  
4 28 4/0 4/0 
Peptidyl-prolyl cis-
trans isomerase 
FKBP1A 
Catalyzes the cis-
trans isomerization of 
proline.  
1 12  1/0 
Thioredoxin 
Protein reduction by 
thiol-disulfide 
exchange. 
2 21 2/0 2/0 
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Our list was enriched in proteins involved in the processing of N-linked glycans 
and disulfide bonds; the following proteins were of particular interest and thus selected 
for further study. Four PDI family members with active thioredoxin-like domains were 
present in our crosslinking experiments: PDI, ERp44, ERp72, and ERdj5. The PDI 
family is a family of 21 related mammalian proteins with at least one active thioredoxin-
like domain that mediates thiol-disulfide exchange although some family members have 
only inactive thioredoxin-like domains133,134. PDI is the most predominant ER-resident 
PDI. It assists with disulfide bond formation, its capable of nonspecific peptide binding, 
and has chaperone functions135. In vitro experiments show that PDI is capable of 
refolding a denatured protein that lacks disulfide bonds136. ERp44 is important in thiol-
mediated retention, a system in which monomers destined for oligomeric complexes are 
retained in the ER until they are properly incorporated into higher order structures137. 
ERp44 is also involved in the quality control of oligomeric proteins containing disulfide 
bonds138. ERp72 is a PDI with narrow substrate specificity139,140. ERp72 specializes in 
processing proteins like LPL that have with multiple disulfide bonds and that form parts 
of oligomeric complexes. ERdj5 accelerates ER associated protein degradation (ERAD) 
by reducing misfolded proteins, and facilitates efficient protein folding by reducing non-
native disulfides141,142. Lastly, we are interested in the glucosyltransferases UGGT1 and 
2. UGGT2 is an isoform of the better-characterized UGGT1 but both proteins localize to 
the ER lumen where they selectively reglucosylate unfolded glycoproteins thus playing 
a role in ER quality control143.   
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Knockdown of Candidate LMF1-interacting Partners Reduces LPL secretion 
We next tested the role of our novel LMF1 binding partners in LPL secretion. PL, 
which does not depend on LMF1 for exit from the ER, served as a negative control for 
changes to the ER protein-folding environment. siRNAs against ERp44, PDI, ERp72, 
UGGT2, ERdj5 and UGGT1 were compared to a scrambled siRNA control (NC). As 
shown in the media fraction of Figure 3.3A-B, knockdown of ERp44, ERp72, UGGT2, 
and ERdj5 decreased secretion of LPL much more dramatically than PL. Knockdown of 
UGGT1 slightly decreased LPL, but not PL, secretion. Unexpectedly, knockdown of PDI 
seemed to increase secretion of both LPL and PL. The knockdown of the LMF1 
interacting partners was measured in the lysate fraction (Fig. 3.3A-B), and for most 
partners knockdown was similar for LPL and PL, as shown in Figure 3.3C.  
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A) and B) HEK293 cells stably expressing LPL-V5 or PL-V5 were transfected with  
scrambled siRNA (NC) or siRNA against the newly identified LMF1-interacting partners. 
Lipase secretion into the media was induced with heparin, and media and lysate 
fractions were collected for analysis. Media fractions were probed with 41a antibody for 
LPL and a C-terminus V5 tag for PL. Lysates were also probed for the respective LMF1 
interacting-partners. GAPDH was used as a loading control. C) siRNA knockdowns 
shown in A and B were performed in triplicate. The intensity of bands for each knocked 
down protein was quantified using Image Lab, and the percent knockdown was 
calculated as described in methods. D) Quantification of lipase secretion normalized to 
the cell number per sample and to secretion with scrambled siRNA. Just like for panel 
C, band intensity was quantified with Image Lab and error bars indicate the standard 
error. 
 
  
Figure 3.3 siRNA knockdown of novel LMF1-interacting partners affects LPL 
secretion. 
D. 
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Novel Partners form Complexes with LMF1 and LPL  
We next set out to determine if the novel LMF1 partners would bind to LMF1, 
LPL, or both. We first purified LMF1 via the His tag after in-cell crosslinking with DSP to 
binding partners. We then performed Western Blots against the interacting partners to 
determine if there was an increase in the apparent molecular weight of the partners in 
samples not treated with DTT. We next treated samples with DTT and looked for bands 
that collapsed down to the expected molecular weight. ERp44, UGGT2 and ERp72 form 
higher-molecular weight complexes with LMF1 when crosslinked with DSP, as shown in 
Figure 3.4, LMF1 panel. Blots were stripped and re-probed using α-His antibody to 
ensure that the complexes contained LMF1 (not shown). We repeated these 
experiments but replaced His-tagged LMF1 with LPL. We found UGGT2, PDI and 
ERp72 in a high molecular weight complex with LPL which was also affinity purified via 
a His tag. Table 3.3 summarizes these results as well as other ER resident candidates 
that according to our findings do not interact with LMF1 or LPL. A horizontal line 
denotes a condition we did not tested for.  
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Figure 3.4 Validation of novel LMF1 and LPL interacting partners. 
Cells stably expressing LMF1-His or LPL-His were induced with tetracycline followed by 
treatment with DSP crosslinker. The His-tagged protein was purified and then samples 
were probed for the indicated interacting partner. A) Pull downs of LMF1-His show that 
LMF1 interacts with ERp44, ERp72, UGGT1, and UGGT2. B) Pull downs of LPL-His 
show that LPL interacts with PDI, ERp72, and UGGT2. 
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pBpa siRNA
Protein 
Candidate LMF1-His LPL-His
LMF1     
loop C
Hinders 
LPL 
secretion
ERp44 yes no yes yes
ERp72 yes yes no yes
UGGT1 yes no  - yes
UGGT2 yes yes  - yes
ERdj5 no no  - yes
Bip no no no  -
Ero1-α no no no  -
Endoplasmin or 
GRp94 no no no  -
PDI no yes no no
ERp57  - no no  -
DSP
Table 3.3 Summary of pull down results for both crosslinkers and LPL secretion 
studies. 
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ERp44, ERdj5 and TRX form Thiol-dependent complexes with LMF1 
Unexpectedly, we saw higher molecular weight bands in the ERp44-LMF1 
samples in the absence of DSP (Fig. 3.4, LMF1-ERp44 panel, + Tet, - DSP, -DTT lane). 
This clue suggests that LMF1 might play an important role in cellular redox 
homeostasis. Because DSP crosslinks can be broken through the addition of a reducing 
agent, we used non-reducing loading buffer for our crosslinked samples prior to SDS-
PAGE. When we used a reducing loading buffer, DSP-independent ERp44-LMF1 
complexes were lost (Fig. 3.4, LMF1-ERp44 panel, + Tet, - DSP, + DTT lane). We thus 
set out to determine if any other LMF1-binding partners formed thiol-dependent 
complexes with LMF1. To do so we collected cells expressing LMF1-His, and quenched 
disulfide exchange in the cells with trichloroacetic acid (TCA) and the addition of N-
Ethylmaleimide (NEM). We purified the complexes via LMF1's His tag and ran non-
reducing gels for Western blots. We probed for the oxidoreductases listed in Table 3.3. 
We also checked the list of proteins identified by mass spectrometry for additional redox 
active proteins. One cytosolic protein, TRX was not initially tested because we focused 
on ER-resident proteins. The unique peptide counts as well as percent coverage for 
TRX is included at the end of Tables 3.1 and 3.2. Westerns for TRX were also 
performed. We found thiol-dependent bands with molecular weights corresponding to 
the protein of interest plus LMF1 using antibodies against ERp44, TRX, and ERdj5 (Fig. 
3.5A, arrows indicate expected molecular weight in lysates and asterisks indicate 
complexes). We did not find ERdj5 in a complex with LMF1 when cells were treated with 
DSP. This may be because DSP could crosslink other more abundant proteins and 
block ERdj5-LMF1 interactions.  
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Because we found ERdj5, ERp44 and TRX in thiol-dependent complexes with 
LMF1, we wanted to determine which cysteines on LMF1 are important for its function. 
LMF1 has several highly conserved cysteines. We mutated cysteines at position 145, 
231, 237, 288, 322, 445, and 453 to alanines by site-directed mutagenesis. The 
positions of these cysteines on LMF1 are shown in Figure 3.5B. We also made a 
complete cysteine mutant, and two compound mutations with both membrane cystines 
(245, 288) and both C-terminal cysteines (445, 453) mutated to alanines. These 
cysteine mutant LMF1 constructs were transfected into cld/cld mouse embryonic 
fibroblasts (MEFs) along with a plasmid expressing LPL-V5. These MEFs are derived 
from mice homozygous (cld/cld) for the combined lipase deficiency mutation, which is a 
truncation mutation in LMF177,81. WT LMF1 and a plasmid expressing GFP served as 
positive and negative controls, respectively. All mutations reduced LPL secretion 
relative to WT LMF1 (Fig. 3.5C, media panel). The effects were most severe at 
positions 237, 288, 322, 445, 453 and the compound and complete mutations. 
However, no LMF1 expression was observed when LMF1 was mutated at position 237 
or at all of the cysteines (Fig. 3.5C, α-LMF1 panel). Thus, positions 288, 322, 445 and 
453 seem to be particularly important for LPL secretion.  
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Figure 3.5 ERp44, ERdj5 and TRX interact with LMF1 in a thiol-dependent manner. 
A) NEM addition stabilizes mixed disulfides of LMF1 with ERdj5, TRX, and ERp44.  
LMF1-His was purified from TCA precipitated cell lysate treated with NEM, then 
samples were probed using antibodies against the indicated interacting partners. Cells 
treated with DTT served as a control.  B) Schematic of the membrane topology of LMF1 
and the location of the conserved cysteine’s tested. C) Secretion of LPL-V5 from cld/cld 
cells transiently transfected with LMF1 bearing the indicated cysteine to alanine 
mutations. Lipase levels in the lysate and pellet, and LMF1 levels in the pellet, are also 
probed. GAPDH serves as a loading control. The data for Figure 3.5C was provided by 
Lindsey J. Broadwell.  
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Levels of Cytosolic TRX Influence LPL, but not PL, secretion 
Because we found TRX in a thiol-dependent complex with LMF1, we reduced its 
cellular levels using siRNA and tested for effects on LPL secretion. As shown in Figure 
3.6A, media panel, reduction of cellular TRX dramatically reduced LPL secretion. 
However, PL secretion was not affected. We also overexpressed thioredoxin-interacting 
protein (TXNIP). TXNIP binds reduced TRX through disulfide linkages and inhibits TRX 
activity144. When TXNIP is overexpressed, LPL, but not PL, secretion is severely 
reduced (Fig. 3.6B, media panel and TXNIP panel). Thus, TRX is not only in a complex 
with LMF1 but is also required for robust LPL secretion. In combination with the data 
from Figure 3.5, these data suggest that LMF1 may connect cytosolic thioredoxin with 
ER-resident oxidoreductases.  
To further probe this connection we next compared sensitivity of cld/cld and 
cld/wt (heterozygous littermates) MEFs to a series of drugs that perturb cellular redox 
homeostasis and protein folding. These drugs were buthionine sulfoximine (BSO), 
dithiothreitol (DTT) and tunicamycin. BSO inhibits synthesis of the reducing agent 
glutathione145. If LMF1 transfers reducing equivalents to the ER, we would expect 
cld/cld cells to be more sensitive to BSO than cld/wt cells. Tunicamycin blocks N-linked 
glycosylation thus causing an accumulation of unfolded glycoproteins in the ER, which 
induces the unfolded protein response (UPR)146. Many of these unfolded proteins are 
destined for ERAD, and thus tunicamycin should increase the demand for ERdj5 to 
reduce their disulfide bonds142. If LMF1 contributes to reduction of ERdj5, cells lacking 
LMF1 should be hypersensitive to tunicamicyn. As a strong reducing agent, DTT blocks 
disulfide bond formation. If LMF1 provides reducing equivalents, we would not expect 
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cld/cld cells to be more sensitive to DTT than cld/wt cell. As shown in Figure 4C, we 
found that relative to cld/wt cells, cld/cld cells were slightly more sensitive to BSO and 
dramatically more sensitive to tunicamycin. However, cld/wt and cld/cld cells were 
equally sensitive to DTT. 
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Figure 3.6 Cellular TRX levels and activity affect LPL, but not PL, secretion. 
A) HEK293 cells stably expressing LPL-V5 or PL-V5 were transfected with scrambled 
siRNA (NC) or siRNA against TRX. Lipase and TRX levels were tested in the media 
and lysate fractions as described in Fig. 3. B) TXNIP overexpression in HEK293 cells 
stably expressing LPL-V5 or PL-V5 hinders secretion of LPL, but not PL. C) MEFS 
homozygous (cld/cld) or heterozygous (cld/wt) for a loss of function mutation in LMF1 
were treated with BSO, DTT, or tunicamycin (Tn). Treated cell and untreated cells were 
counted, and the percent of surviving cells was calculated. The difference between 
survival cld/cld and cld/wt cells for BSO and tunicamycin treatment were statistically 
significant as determined by a 2-tailed student’s t-test (p < 0.05). Survival of cld/cld and 
cld/wt cells treated with DTT was not significantly different (p > 0.05). 
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Discussion 
Our goal was to understand how LMF1 promotes LPL maturation. From our 
lipase chimeras we learned that the C-terminus of LPL is important for LPL’s secretion 
and that only the C-terminus of LPL interacts physically with LMF1. From our mass 
spectrometry data we derived a role for LMF1 in ER redox homeostasis. Through our 
mixed disulfide and DSP crosslinking experiments we found five novel, ER-resident 
binding partners of LMF1 (ERp44, ERp72, ERdj5, UGGT1, and UGGT2). Protein 
downregulation via siRNA validates the requirement of these five candidates for LPL 
secretion. ERp44 reduces oxidized subunits of proteins such as adiponectin destined to 
assemble into higher molecular weight complexes147. ERp44 also uses a thiol linkage to 
retrieve Golgi-localized orphan subunits of proteins (such as IgM) intended for disulfide-
linked oligomers back to the ER148. The disulfide bond between ERp44 and the orphan 
subunit must then be reduced. ERdj5 is known to reduce disulfide bonds for proteins 
destined for ERAD as well as nonnative disulfides required for the productive folding of 
substrates such as the LDL receptor141,142. ERdj5's thioredoxin domain has the lowest 
reduction potential among the PDI family, and hence can reduce other PDIs but can't be 
reduced by them149. The mechanism by which ERdj5 is reduced once its active site is 
oxidized is unknown, but it has been suggested that ERdj5 could be reduced by 
glutathione or other small redox cofactors141,149. We suggest that LMF1 facilitates the 
reduction of these proteins, resolving these outstanding mysteries. 
We also found an important role for cytosolic thioredoxin in LPL secretion. First, 
we detect the formation of a mixed disulfide bond between LMF1and TRX. Aditionally, 
TRX downregulation via siRNA as well as inhibition of cytosolic TRX by overexpression 
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of TXNIP decreases secretion of LPL. These data suggest that LMF1 provides a 
physical and functional linkage between cytosolic TRX and ER-resident 
oxidoreductases. LMF1 thus resembles DsbD, the bacterial periplasmic protein that 
transfers electrons from cytosolic TRX to substrates in the periplasm. DsbD has no 
known homologue in eukaryotes, and it was widely assumed that glutathione powered 
disulfide reduction in the ER150. However, a recent study showing that depletion of ER-
resident glutathione had no effect on disulfide bond isomerization, the reduction-
dependent degradation of ERAD substrates, or the induction of the UPR151. These data 
led the authors to conclude that an alternative small molecule or a eukaryotic 
homologue to DsbD was responsible for providing reducing equivalents to 
oxidoreductases in the ER151.  
We propose that although LMF1 was not previously recognized to have a role in 
redox homeostasis in the ER, it fills this role. This role for LMF1 was not readily 
apparent because although our data shows that LMF1 has strong functional homology 
to DsbD, the two proteins have only weak sequence homology. Unlike DsbD, LMF1 is 
not annotated as containing a thioredoxin-like domain. LMF1’s conserved cysteines are 
not arranged in a canonical C-X-X-C motif. However, a pairwise alignment of LMF1 and 
DsbD revealed a stretch of about 100 amino acids in the C-terminus of both proteins 
with 23% sequence identity (Fig. 3.7). This is the C-terminal ER/periplasmic region of 
both proteins and contains residue C453 of LMF1 and the final redox-active cysteine 
pair of DsbD. Perhaps LMF1 keeps ERdj5 in a reduced state to promote isomerization 
of non-native disulfide bonds on LPL in a manner similar to DsbD reduction of DsbC to 
promote disulfide isomerization in prokaryotes. At this time we do not know if LMF1 
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uses a cysteine relay similar to DsbD, and will resolve its mechanism of action through 
future studies.   
However, analysis of LMF1-related proteins supports the idea that, like DsbD, it 
uses some mechanism for transmembrane electron transport. The protein family 
database, or Pfam, groups proteins into families based on sequence alignments and a 
profile hidden Markov model (HMM) analysis. Related families are grouped into clans, 
which are families with sequence, structure, or profile-HMM similarity152. LMF1 belongs 
to a clan that includes the archaeal and bacterial membrane proteins DoxD, DoxX, and 
MauE. Strikingly, these three transmembrane proteins are all involved in redox 
reactions. DoxD is a multipass membrane protein that, with its binding partner DoxA, 
oxidizes thiosulfate to reduce quinone153. DoxX is a recently identified Mycobacterium 
tuberculosis multipass membrane protein that forms a complex with SodA and SseA to 
link detoxification of superoxide radicals generated during the phagocyte oxidative burst 
with cytosolic thiol homeostasis154. MauE is a multipass membrane protein from 
Paracoccus denitrificans. MauE and its partner, MauD, are involved in the oxidation of 
methylamine155.  
We propose that LMF1 may be part of a center for folding disulfide bond-
containing proteins that are functional as oligomers, such as LPL. First, these proteins 
may have a special need for reduction of mispaired disulfide bonds to allow additional 
rounds of folding. Next, many secreted proteins have both N-linked glycans and 
disulfide bonds, and processing of these two postranslational modifications are 
intimately linked156. We found peptides specific to both UGGT1 and UGGT2 in our 
analysis of LMF1-binding partners. UGGT1 is a glucosyltransferase that functions in ER 
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quality control of glycoproteins, but the function of UGGT2, an isoform of UGGT1, is still 
a subject of debate143. UGGT1 acts after the initial processing of an N-linked 
oligosaccharide. If the glycoprotein has not achieved its native conformation, the 
glucosyltransferase UGGT1 aids in folding by adding back a glucose residue, allowing 
another round of association with calnexin and calreticulin143. Although some studies 
have concluded that UGGT2 is enzymatically inactive143,157, other studies show that it 
has glycosyltransferase activity when tested on a synthetic substrate158. Additionally, 
studies in C. elegans showed that the two isoforms played different roles in response to 
ER stress159. We found that siRNA knockdown of both UGGT1 and UGGT2 resulted in 
loss of LPL secretion, but the effect was more pronounced for UGGT2. LPL is thus the 
first known physiological substrate for UGGT2. Intriguingly, UGGT2 is expressed in 
heart and skeletal muscle, an expression profile similar to LPL143. We also found 
UGGT2 in a complex with LMF1. These data lead us to speculate that UGGT2 may 
partner with LMF1 to assist in the folding of secreted, disulfide rich, oligomeric 
glycoproteins.  
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Figure 3.7 Schematic of LMF1 and DsbD. 
A pairwise alignment was performed using Tcoffee. The C-terminal ER or periplasmic 
region of the two proteins was 23% identical. Conservation starting after the last 
transmembrane segment is shown. Red represents good conservation and green 
represents poor conservation. Key cysteines are marked with a triangle. 
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 CONCLUSIONS AND FUTURE DIRECTIONS CHAPTER 4:
Introduction 
This thesis work provides data that has shed light on the role of LMF1 in dimeric 
lipase maturation. We learned from the N-terminal domain truncations of LMF1 that full 
length FL LMF1 is necessary for the maturation of LPL. Our studies with the lipase 
chimeras show that the C-terminus of LPL is important for LPL’s secretion. Furthermore, 
our crosslinking pulldowns revealed that the C-terminus of LPL interacts with LMF1 thus 
we have narrowed down the site of interaction of LMF1 on LPL. However, the 
mechanism by which LMF1 is retained in the ER remains unknown. We found protein-
protein interactions between LMF1 and ERp44 with different crosslinkers (Table 3.3) 
plus mixed disulfide formation from the NEM studies (Fig.3.5A). ERp44 is known to 
participate in thiol-mediated retention in the ER eukaryotes. The oxidoreductase Ero1-α 
lacks an ER retention signal but Ero1-α is retained in the ER though a mixed disulfide 
with ERp44160. LMF1 also lacks a known ER retention signal, thus we used siRNA 
against ERp44 and the ER marker Sec16 to determine if ERp44 helps to retain LMF1 in 
the ER. However, downregulation of ERp44 does not hinder the ER localization of 
LMF1 (Figure 4.1). 
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Figure 4.1 ERp44 is not responsible for ER retention of LMF1. 
A) LMF1-His HEK293 cells transiently transfected with: A) scrambled siRNA as negative 
control (NC) or B) 20 nM of siRNA against ERp44. The merged images are shown, 
LMF1 is represented in green while Sec16 is red. After 24 hrs post-siRNA transfection, 
the cells were induced with 1 ug/mL of tetracycline. Cells were fixed with 4% 
paraformaldehyde 48 hrs post-transfection and permeabilized with 0.1% triton X-100. 
Sec16 antibody was used at 1:100 and anti-His at 1:200 with Alexa Fluor 594 (1:500) 
and 488 (1:800) respectively for fluorescence detection.   
 
 
  
A. B. 
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An early hypothesis for how LMF1 promotes lipase maturation was that LMF1 
acts as a cargo receptor for dimeric lpases. Homozygous LMF1 mutations in patients 
result in low plasma levels of dimeric lipases. This phenotype is reminiscent of other 
disorders resulting from mutations in cargo receptors. For example, patients with a rare 
inherited bleeding disorder (Factor V/VIII deficiency) have low plasma levels of factor V 
and VIII due to mutations in one of two proteins that form a cargo receptor complex in 
the ER161. A special client-specific cargo receptor is needed for incorporation of the 
coagulation factors into COPII vesicles for proper incorporation in the secretory 
pathway. To investigate if LMF1 is a cargo receptor required for ER exit of dimeric 
lipases, we used immunofluorescence to determine if LMF1 localizes to COPII vesicles. 
Sec16, a common COPII vesicle marker, has a punctate pattern characteristic of COPII 
vesicles (Fig. 4.2, second panel)162. However, LMF1 shows a tubular pattern 
characteristic of other chaperones such as GRP78, calnexin, and calreticulin that 
localize to the peripheral ER (Fig. 4.2, third panel)81. Based on the distinct expression 
patterns of LMF1 and Sec16 we concluded that LMF1 is not a cargo receptor.   
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Figure 4.2 LMF1 does not localize to ER exit sites. 
Immunofluorescence of LMF1 with the COPII marker Sec-16 in COS-7 cells. Scale bar 
represents 20 µm. LMF1 and Sec16 were detected as in Figure 4.1. 
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Our most interesting finding was the discovery of novel interacting partners of 
LMF1 that are essential for LPL secretion and that have revealed a role in ER-redox 
homeostasis for LMF1. We report LPL as the first known physiological substrate for 
UGGT2. Additionally, we found redox-active proteins among the novel-binding partners 
of LMF1. These redox-active proteins are the cytosolic thioredoxin (TRX) and the ER 
resident proteins ERp72, ERp44, and ERdj5. Sequence alignment of LMF1 across 
species reveals that LMF1 has several conserved cysteines (Fig. 4.3) of which we 
found positions 288, 322, 445, and 453 to be needed for LPL secretion. Similarly, DsbD 
has three domains, each with a conserved pair of reactive cysteines important for the 
electron transfer from cytosolic TRX163. Furthermore, alignment of the C-
terminal/periplasmic region of LMF1 and DsbD respectively contains a stretch of about 
100 amino acids with 23% sequence identity (Fig. 3.7). Our findings lead us to propose 
that LMF1 is also a transmembrane electron transporter like DsbD thus it promotes 
protein folding by connecting cytosolic TRX to ER-resident oxidoreductases such as 
ERp72, ERp44, and ERdj5.  
Why full length is required for lipase maturation remains unanswered. The 
cysteines important for LPL maturation are in the DUF122 domain81,84,117. The DUF122 
domain was already known to be important for dimeric lipase maturation. We also know 
that loop A is not required for LPL binding82. Perhaps loop A is needed for ER-retention 
of LMF1 or for protein-protein interactions with one of our novel LMF1 binding partners 
that reside in the ER lumen.   
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Figure 4.3 Sequence alignment of LMF1 reveals cysteine conservation. 
Red arrows denote nine conserved cysteines of LMF1. We performed point mutations in 
all of them (data not shown for C87) except for 188 but only saw an inhibitory secretion 
effect for LPL with the cysteines in positions 288, 322, 445, and 453. These cysteines 
localize to the DUF1222 domain of LMF1 (for the topology of LMF1 see Fig. 1.3). This 
sequence alignment was performed using Clustal Omega.  
 
wrap;">CLUSTAL O(1.2.1) multiple sequence alignment
SP|Q96S06|LMF1_HUMAN   MRPDSPTMAAPAESLRRRKTGYSDPEPESPPAPGRGPAGSPAHLHTGTFWLTRIVLLKAL 60
SP|Q3U3R4|LMF1_MOUSE   MRPDSLVMAAPEGSLRKRKVGGAEHSPASQPSLARDPADSPARLHTGTFWLTRIVLLRAL 60
SP|Q0P5C0|LMF1_BOVIN   -------MAAPRESLRRRKAGAGDPEPEAPPGQGRDLKGRPARLRAGTFWLTRIVLLRAL 53
TR|J9P7V8|J9P7V8_CANLF -------MAAPEESLRKRKAGKAGGGPGSPPGPGLDPTGCSAGLRAGTFWLTRIVLLRAL 53
TR|F7A1Z9|F7A1Z9_XENTR ------------------------------------------------------------
                                                                                   
SP|Q96S06|LMF1_HUMAN   AFVYFVAFLVAFHQNKQLIGDRGLLPCRVFLKNFQQYFQDRTSWEVFSYMPTILWLMDWS 120
SP|Q3U3R4|LMF1_MOUSE   AFIYFVAFLVAFNQNKALIGDRGLLPCKLYLKNVQEYFQGSTGWAAWTYAPTIMWLLDWS 120
SP|Q0P5C0|LMF1_BOVIN   AFVYFVAFLVAFHQNKQLIGDRGLLPCRAYLQSVQRHFGGRVSWDALSYAPTILWLLDWS 113
TR|J9P7V8|J9P7V8_CANLF AFIYFVAFLVAFHQNKQLIGDWGLLPCRAYLKSVQQYFRGRVGWDAVSYAPTVLWLLDWS 113
TR|F7A1Z9|F7A1Z9_XENTR ------------------------------------------------------------
                                                                                   
SP|Q96S06|LMF1_HUMAN   DMNSNLDLLALLGLGISSFVLITGCANMLLMAALWGLYMSLVNVGHVWYSFGWESQLLET 180
SP|Q3U3R4|LMF1_MOUSE   DMNFNLDLIALLGLGISSFVLVTGCANMILMTALWALYMSLVNVGQIWYSFGWESQLLET 180
SP|Q0P5C0|LMF1_BOVIN   HMDANLDALALLGLGISSFILVSGCANMVLMAALWVLYMSLVNVGQIWYSFGWESQLLET 173
TR|J9P7V8|J9P7V8_CANLF HMDSNLDALALLGLGVSSFVLVTGCANMVLMATLWVLYMSLVNVGQIWYSFGWESQLLET 173
TR|F7A1Z9|F7A1Z9_XENTR ------------------------------------------------------------
                                                                                   
SP|Q96S06|LMF1_HUMAN   GFLGIFLCPLWTLSRLPQHTPTSRIVLWGFRWLIFRIMLGAGLIKIRGDRCWRDLTCMDF 240
SP|Q3U3R4|LMF1_MOUSE   GFLGIFLSPLWTLSRLPKNTPTSQIVLWGFRWLIFRIMLGAGLIKVRGDKCWLDLTCMDF 240
SP|Q0P5C0|LMF1_BOVIN   GFLGIFLCPLWTLSALPRGTPTSWVVMWGFRWLIFRIMLGAGLIKIRGDRCWRDLTCMDF 233
TR|J9P7V8|J9P7V8_CANLF GFLGIFLCPLWTLSRLPRGTPPSRIVLWGFRWLIFRIMLGAGLIKIRGDRCWRDLTCMDF 233
TR|F7A1Z9|F7A1Z9_XENTR -------------------------------------LALLGSLRVFTDRSWH-LSAFSF 22
                                                            :   * :::  *:.*  *:.:.*
SP|Q96S06|LMF1_HUMAN   HYETQPMPNPVAYYLHHSPWWFHRFETLSNHFIELLVPFFLFLGRRACIIHGVLQILFQA 300
SP|Q3U3R4|LMF1_MOUSE   HYETQPVPNPIAYYLHRSPWWFHRFETLSNHFVELLVPFFLFLGRRMRILHGVLQILFQV 300
SP|Q0P5C0|LMF1_BOVIN   HYETQPVPNPVAYFLHRSPWWFHRFETLSNHFLELVVPFFIFLGRRMCIVHGALQVLFQV 293
TR|J9P7V8|J9P7V8_CANLF HYETQPVPNPVAYFLHQSPWWVHRGETLGNHFVELVVPFFIFLGRRMCVLHGALQILFQV 293
TR|F7A1Z9|F7A1Z9_XENTR PLQTQPVPNPLAYYMHRNPWWFHQFETLFNHFIELVVPFFIFLGRRMCLIHGILQVLFQV 82
                         :***:***:**::*:.***.*: *** ***:**:****:*****  ::** **:***.
SP|Q96S06|LMF1_HUMAN   VLIVSGNLSFLNWLTMVPSLACFDDATLGFLFPSGPGSLKDRVLQMQRD-IRGAR-PEPR 358
SP|Q3U3R4|LMF1_MOUSE   ILIISGNLSFLNWLTIVPSLACFDDAALGFLFPSGPQGLKKQVLEIQREDTQRVQPKPRD 360
SP|Q0P5C0|LMF1_BOVIN   VLIISGNLSFLNWLTIVPSLACFDDATLGGLFPSGPGRLKDQVLKIQEEETRGAR-APRT 352
TR|J9P7V8|J9P7V8_CANLF ILIISGNLSFLNWLTMVPSVACFDDATLGFLFPSGPGGLKYRVLKMQEEAARGAL-APLR 352
TR|F7A1Z9|F7A1Z9_XENTR LLILSGNLSFLNWLTILPSIACFDDASLGFLFSSKKGSVKHQVSEIQAEKSAGGG-PSKT 141
                       :**:***********::**:******:** ** *    :* :* ::* :           
SP|Q96S06|LMF1_HUMAN   FGSVVRRAANVSLGVLLAWLSVPVVLNLLSSRQVMNTHFNSLHIVNTYGAFGSITKERAE 418
SP|Q3U3R4|LMF1_MOUSE   RGCLVRQVVNISLGILVAWLSVPVVINLLSSRQIMNTSFNPLRIVNTYGAFGSVTKERTE 420
SP|Q0P5C0|LMF1_BOVIN   RGSVARGTVNLALGILVAWLSIPVVLNLLSPRQVMNSSFNPLRIVNTYGAFGSITRERTE 412
TR|J9P7V8|J9P7V8_CANLF YGCMVRRAVHLALAALVAWLSVPVVLNLLSPTQIMNTSFNPLRIVNTYGAFGSITKERTE 412
TR|F7A1Z9|F7A1Z9_XENTR YGCYVRQLVHLSLGVLIIFLSVPVVLNLLSSKQVMNTSFNPLKIVNTYGAFGSITKERTE 201
                        *. .*  ..::*. *: :**:***:****  *:**: ** *:**********:*:**:*
SP|Q96S06|LMF1_HUMAN   VILQGTASSNASAPDAMWEDYEFKCKPGDPSRRPCLISPYHYRLDWLMWFAAFQTYEHND 478
SP|Q3U3R4|LMF1_MOUSE   VILQGTVSPNASAPDAVWEDYEFKCKPGDPWRQPCLISPYHYRLDWLMWFAAFQTYEQNE 480
SP|Q0P5C0|LMF1_BOVIN   VILQGTASANASAPDSAWEDYEFKCKPGDPRRRPCLISPYHHRLDWLMWFAAFQTYEHNE 472
TR|J9P7V8|J9P7V8_CANLF VILQGTAAPNASSPDAVWEDYEFKCKPGDPGRRPCLISPYHYRLDWLMWFAAFQTYEHNE 472
TR|F7A1Z9|F7A1Z9_XENTR VVLQGTSSSDPSDPGAVWEDYEFKCKPGNLTRPPCVISPYHYRLDWLMWFAAFQTYEQNE 261
                       *:**** : : * * : ***********:  * **:*****:***************:*:
SP|Q96S06|LMF1_HUMAN   WIIHLAGKLLASDAEALSLLAHNPFAGRPPPRWVRGEHYRYKFSRPGGRHAAEGKWWVRK 538
SP|Q3U3R4|LMF1_MOUSE   WILHLAGKLLAGDSEALALLAVNPFEGRTPPRWIRGEHYRYKFSLPGGQHATQGKWWIRK 540
SP|Q0P5C0|LMF1_BOVIN   WIIHLAGKLLANDAQALSLLARNPFEGRDPPRWVRGEHYRYKFSRPGGRHAAEGKWWIRR 532
TR|J9P7V8|J9P7V8_CANLF WIIHLAGKLLANDASALSLLAVNPFEGRAPPRWLRGEHYRYKFSRPGGPHAAAGKWWLRK 532
TR|F7A1Z9|F7A1Z9_XENTR WIIHLAGKLLANDRSASSLIAVNPFYEREPPRWIRGEHFRYKFSRPWGTHASKGKWWIRK 321
                       **:******** * .* :*:* ***  * ****:****:***** * * **: ****:*:
SP|Q96S06|LMF1_HUMAN   RIGAYFPPLSLEELRPYFRDRGWPLPGPL----- 567
SP|Q3U3R4|LMF1_MOUSE   RIGPYFPPLRLEDLKEYFKTREWPLPEPPSRHTR 574
SP|Q0P5C0|LMF1_BOVIN   RLGPYFPPLSRQDLRGYFTSRQWPYPEPE----- 561
TR|J9P7V8|J9P7V8_CANLF RIGPYFPPVSLRDLEDYFRSREWPHPAVDVD--- 563
TR|F7A1Z9|F7A1Z9_XENTR RIGPYFPPLNLPGLKKFFQSRSWPLPVSK----- 350
                       *:* ****:    *. :*  * ** *        
</pre></body></html>
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Future directions 
Confirming the role of LMF1 in electron transfer 
I have generated HEK293 stable cell lines expressing point mutations of 
cysteines to alanines in the four cysteines important for LMF1 function (288, 322, 445, 
and 453). Position 322 is exposed to the cytosol so we have hypothesized this cysteine 
is crucial for formation of the mixed disulfide bond with TRX. Alternatively, DsbD 
transfers the two electrons across the cytoplasmic membrane by a pair of cysteines that 
are predicted to be within the transmembrane segments164. Thus C288 of LMF1 could 
be the cysteine that forms a mixed disulfide bond with TRX. Positions 445 and 453 
localize to the C-terminal domain of LMF1 which faces the ER-lumen thus we have 
hypothesized these two residues can form mixed disulfide bonds with ERp44 or ERdj5. 
We will determine if our mutants abolish the formation of these mixed disulfide bonds by 
adding the alkylating agent NEM to cell lysates from the stable cell lines expressing the 
point mutations of LMF1. 
Based on the formation of mixed disulfides between LMF1 with TRX and ERdj5, 
we hypothesized that LMF1 maintains ERdj5 in a reduced state to promote 
isomerization of non-native disulfide bonds on LPL in eukaryotes. This role for LMF1 
would be similar to the role of DsbD in reducing DsbC in prokaryotes and ERdj5 would 
participate in isomerization of disulfide bonds. An in vitro experiment with purified LMF1, 
TRX, LPL and PDIs can further our understanding of the role of LMF1 in redox 
homeostasis within the ER as well as the role of the three PDIs we detected as novel 
interacting partners of LMF1. LMF1 can be purified from SF9 cells as we have done 
previously165. Since LMF1 is a five segment transmembrane protein, phospholipid 
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bilayer nanodiscs will be used to prevent aggregation and provide a more physiological 
environment166,167. LPL can be purified from bovine milk168 and denatured with 
guanidinium hydrochloride to study the folding effects of the PDIs. LPL folding can be 
assessed by the measurement of LPL activity using a fluorescent triglyceride analogue169. 
Experiments can be performed with LPL, LMF1, a PDI and with/without TRX. If TRX 
addition promotes LPL folding significantly with PDI addition, we can conclude that 
LMF1 transfers electrons from TRX to the PDIs. Further more, by adding ERp72, ERdj5, 
and ERp44 separately we can determine which is the primordial PDI required for proper 
folding of LPL. 
To determine if there is electron transfer due to disulfide bond oxidation and 
reduction, LMF1 can be separated into domains containing cysteine pairs and 
expressed simultaneously similar to what was done with DsbD when determining that 
the electron transfer occurs via a disulfide bond cascade170. LMF1 can be separated 
into two pieces taking into consideration that all the cysteines of LMF1 important for LPL 
maturation are in the DUF122 domain. These pieces are a C-terminal truncation 
containing the first four transmembrane domains of LMF1 and an N-terminal truncation 
containing the C-terminal soluble domain, which harbors a cysteine pair. The ER 
retention signal used previously will be added to the C-terminal truncation165. Each 
segment of LMF1 must contain a different tag so the oxidation state of each segment of 
LMF1 can be assessed as was done for DsbD170. Additionally, the cysteines not 
essential for LPL maturation should be replaced by alanines for each segment. 
Importantly, for this assay we need to determine the oxidation state of a substrate of 
LMF1. If ERdj5 does enhance LPL activity in the in vitro experiment it could be used as 
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LMF1’s substrate. The oxidation state of ERdj5 can be determined by acid trapping cell 
lysates and alkylation of free cysteines with NEM. Expression of LMF1 constructs (in a 
knock out cell line for LMF1) will reveal the ability of LMF1 in reduction of ERdj5. A 
higher molecular weight band represents the reduced form of ERdj5 due to the 
incorporation of the alkylating agent. If the co-expression of both LMF1 segments does 
not restore the electron transfer activity of LMF1, there would be accumulation of ERdj5 
in the oxidized state (lower molecular weight band). Conversely, if the co-expression of 
both segments of LMF1 restores activity, most of the ERdj5 will be detected in the 
reduced state. A cell line knocked out for LMF1 is required for this experiment.  
Searching for other substrates of LMF1 
LMF1 is ubiquitously expressed81,86, however the dimeric lipases are not. Thus 
LMF1 must be important for folding other proteins in the tissues that do not express 
dimeric lipases. Our newly found role for LMF1 as a transporter of electrons from the 
cytosol to ER-resident oxidoreductases suggests that in other tissues, LMF1 is 
important for folding of proteins with a high number of disulfide bonds like the dimeric 
lipases. We have reviewed our mass spectrometry data from our DSP and pBpa 
crosslinking studies and selected the top 10 (by peptide count) secreted proteins 
identified as LMF1 binding partners (Table 3.1). Most the protein candidates are 
oligomers that are enriched in disulfide bonds. Future experiments include expression of 
these candidates in cld/cld and cld/wt cells to determine if they are not secreted in 
cld/cld cells due to the expression of the truncated form of LMF1.  
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Sample
Disulfide 
BondsName
pBpa
pBpa
pBpa
pBpa
pBpa
Fibronectin
Aggrecan core
Protein
Biglycan
Hyaluronan/ proteo-
glycan link protein
Cartilage oligomeric 
matric protein 24
15
29
DSP
DSP
Table 2: Secreted Proteins
DSP
5
Oligomeric 
State
dimer (ECM)/
monomer (blood)
DSP
DSP
0
4
3
5
29
2
Ig gamma-1
chain C
Protein S100-A8
Integrin beta 1 heterodimer
Ig gamma-2
chain C
Capthesin D
heteroligomer
heteroligomer
heteroligomer
homodimer
heteroligomer
monomer
pentamer
heteroligomer
Table 4.1 Secreted protein candidates for LMF1 substrates. 
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Final remarks 
LPL is the main lipase for triglyceride clearance within the capillary lumen and 
one third of the USA adult population has high lipid levels. Thus we sought to determine 
the role of LMF1 in LPL maturation. First, using a truncation approach we found that 
every loop of LMF1 facing the ER is necessary for the maturation process to take place. 
Second, crosslinking followed by proteomics and data validation revealed that LMF1 
mainly interacts with proteins involved in oxidative folding. Furthermore, the utilization of 
drugs that modify the ER environment point towards a role in ER redox homeostasis for 
LMF1. Additionally, LMF1 has conserved cysteines in a similar manner than DsdD thus 
we have concluded that LMF1 might be the long sought for eukaryotic homologue of 
DsbD. As a next step, it remains to be determined if LMF1 utilizes a cysteine cascade 
as a means to transfer reducing equivalents into the ER lumen similarly to DsbD in 
prokaryotes. This newly found role for LMF1 provides an explanation for the expression 
of LMF1 in tissues that lack LPL and other dimeric lipases and our proteomics data has 
provided a starting point in the search for other substrates of LMF1. 
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